

Treating Addicted Survivors of Trauma



Fall - Spring 2020-2021

J. Eric Gentry, PhD, LMHC Board-Certified Expert in Traumatic Stress

TRAUMADDICTION

Treating Addicted Survivors of Trauma

Hello. I am excited to get to facilitate this course with you. In many ways, I have been preparing to teach this material since I started in the caregiving field in 1982. In 1988, I surrendered a long battle with addiction and began my journey of recovery. In 1990, I started in private practice. Shortly after getting clean I began developing florid symptoms of Posttraumatic Stress Disorder. I began outpatient psychotherapy for myself in 1992. My first day in therapy I told my therapist, "Charlie, I don't deserve to be here. I work with people who have *real* trauma." I have an ACE score of nine, yet I did not comprehend this as trauma.

As I began to work through the traumas of my past, using an abreactive treatment process, I became flooded with flashbacks and nightmares that significantly compromised my ability to function. Within a month of completing my credentialing as a Certified Addiction Counselor in 1993 and on a trip to Oakland to get certified in biofeedback, I relapsed in my recovery from addiction. It took 17 long months for me to start to put clean-time together again—even though I was attending 12-Step meetings fervently. In the Spring of 1995 after a fatal motor vehicle accident, from which I was resuscitated, I restarted my recovery in earnest. I have been clean since then. Staying clean meant I had to make some changes and one of those changes was ending my marriage.

Before I relapsed, I attended a Level I training in EMDR and began to progressively treat more and more trauma survivors in my private practice. I discovered that I had a gift for working with survivors and found it very rewarding. After my divorce in 1995, I started a year-long fellowship in Psychotraumatology at the WVU School of Medicine working with Louis Tinnin, MD. We started the very first intensive outpatient/partial hospitalization treatment program for trauma and dissociation that year and I grew immensely as a clinician. Following that fellowship in May of 1996, I had a couple friends drive me to Maine and I thru-hiked the Appalachian Trail Southbound. When I completed the Trail, I began my doctoral studies at Florida State University where I studied with Professor Charles Figley. He and I started the first Traumatology Institute there in 1997. In 2001, I took the institute to the University of South Florida where I co-directed the program with Michael Rank, PhD. When that institute disbanded I moved to Sarasota in 2004 to start a private practice. In 2009, with two other colleagues, we started the International Association of Trauma Professionals. And in 2017, I moved to Phoenix and purchased part ownership in the Arizona Trauma Institute where I live today

Since 1991, I have worked with hundreds of addicted survivors of trauma. I am grateful to Katie Evans and J. Michael Sullivan for writing *Treating the Addicted Survivor of Trauma* in 1995. They were the pioneers of this work and the first to advocate for treating both trauma and addiction simultaneously. It is upon their shoulders that I stand to bring this training to you in the hopes that no one else ever need die from the horrors of addiction or traumatic stress.

Healing Trauma: Simple not Easy

I have treated people who suffer the effects of trauma for over 30 years. In the beginning, I was terrified as I sat across from these survivors who put their hope and trust in me to help them navigate through the dark tunnel of traumatic stress. I was afraid that I would not be able to help them, or worse, that I would cause them harm. As a result of this fear, I became a very cautious therapist. With my anxious and overly cautious approach, I can see clearly now how I was actually causing harm and thwarting treatment—although I would have vehemently argued this 20 years ago. My anxiety had its upside though, as it compelled me to accrue more and more training. By the mid-90s, I had become trained in every known treatment, the whole "alphabet soup" of protocols, which had shown efficacy and/or effectiveness in treating traumatic stress. These include: Eye Movement Desensitization and Reprocessing (EMDR I & II); Traumatic Incident Reduction (TIR), Neuro-Linguistic Programming (NLP), TRI-Method, CBT protocols (DTE, CPT, SIT, etc), Dialectical Behavioral Therapy (DBT), Gestalt, Psychodynamic methods, Structural & Strategic Treatment for Dissociative Disorders, Thought Field Therapy(TFT), Somatic Experiencing (SE), Emotional Freedom Techniques (EFT), Hypnotherapy, and Critical Incident Stress Management.

In 1995-96, I completed a fellowship in psychotraumatology at WVU's School of Medicine, where I studied with Louis Tinnin, MD—a man Bessel van der Kolk has named the 20th Century's Pierre Janet. Lou is a genius in working with traumatic stress. He turned Pierre Janet's work of the 1880's into a comprehensive treatment model for effectively treating trauma and dissociation. I was able to assist in some of the research that demonstrated the effectiveness of this treatment. Lou taught me two very important ingredients in successfully treating trauma: the value of narrative and a fearless approach of the client's traumatic material.

After I completed this fellowship, I began my doctoral work at Florida State University where I studied under Charles Figley, PhD. Charles will probably become known by history as one of the most important people in the development of the field of Traumatology. His research in the late 1970s help lead to the diagnosis of PTSD being included in the DSM III. He was the first president of the International Society for Traumatic Stress Studies and was the first editor of the Journal of Traumatic Stress. It was an honor to have him as my major professor. In 1997, I assisted Charles in the development of the curricula for the Traumatology Institute at FSU and became one of the original faculty. In that first year, we won the UCEA award for the best continuing education program in the country. Since that time, as faculty and Associate Director of the Traumatology Institute at FSU, co-director the International Traumatology Institute at USF, and owner of Compassion Unlimited in Sarasota, I have trained nearly 100K professionals in some form of traumatic stress intervention.

In my doctoral coursework, I took the course that we all have to take—the one in which we learn to critically evaluate scientific writing. For my work in this particular course, I wanted to evaluate all the treatments for traumatic stress that had demonstrated effectiveness. In the process of doing this, I decided to ask the research question: "Are there any ingredients in

trauma treatment that are demonstrated to be important to all effective treatments?" After completing a qualitative analysis of the all Discussion sections of each of the articles I reviewed, I discovered that there was a resounding "yes" answer to this question. Integral to almost every effective treatment is the combination of some form of exposure to the traumatic material paired with relaxation.

After reviewing the work of Patricia Resick (1988, 1993), Charles Marmar (1989) and James Pennebaker (1989, 1997), and from my own experience of training with Lou, it became obvious to me that the type of exposure was very important. If we could help survivors construct *complete narratives* of their traumatic experiences while in a *relaxed state,* we could help them to accelerate healing of their traumatic stress symptoms. By facilitating this important narrative process, not only are we assisting them with confronting the traumatic material, we are also helping them to structure the intrusive sensory traumata into language. These previously mentioned researchers have been able to demonstrate that effective narrative construction has a powerful ameliorative effect upon the intrusive symptoms of trauma (i.e., flashbacks and nightmares). Virtually every treatment that demonstrated effectiveness with traumatic stress utilized some form of narrative (exposure) paired with some form of relaxation.

As I progressed in my understanding of central nervous system functioning and especially understanding the role of perceived threat and sympathetic dominance in the etiology of traumatic stress symptoms, I began to see ever more clearly the importance of relaxation. Integrating the work of Bob Scaer (2001; 2006) into my own research on relaxation, I began to see that as a person is able to develop and maintain parasympathetic dominance (i.e., relaxation), then symptoms abate. Through working with Emergency Medical Technicians, Neuro-Muscular Therapists, as well as several psychiatrists and neurologists, I stumbled onto the discovery of how 20-30 seconds of pelvic floor relaxation (e.g., psoas, sphincter, and pubiocoxyx, or Kegel, muscles) precipitates parasympathetic dominance. This simple relaxation strategy fortifies the individual with (a) comfort in their body; (b) total access to memory, language and neocortical functioning; and (c) the capacity for intentional living (more about this in the training). If and when a trauma survivor is able to keep their body relaxed, they no longer suffer symptoms.

For a while I thought and taught that these were the **only two** crucial ingredients to effective treatment of traumatic stress—narrative/exposure and relaxation (reciprocal inhibition). In 1999, Hubble, Duncan, and Miller released, in my opinion, the single most import text of the past decade—*The Heart & Soul of Change*. This book is chocked full of paradigm-shifting information. One of the most important truths to come from their huge meta-analytic study was what they learned about predictors of positive outcomes in psychotherapy. They found that the MOST important predictor of positive outcomes in our patient's psychotherapy has nothing to do with the therapy itself—it is occurrences that happen outside of therapy that account for over 40% of positive outcomes. Then, of the 60% that we, as helpers, can influence we find that 30% is contingent upon the development and maintenance of a good therapeutic relationship. The remaining 30% is split equally between positive expectancy (which has also been called either "hope" or "placebo") and techniques/models. There is a good argument that


the process of developing expectancy/hope/ placebo is also a relational function. If this is so, then that means the degree to we can influence positive outcomes for our clients, 75% is contingent upon relational factors and 25% is contingent upon technical and/or philosophical factors. This data confirms what I, as a professional care provider for nearly three decades, have always intuited—people heal people! It is not EMDR, or CBT, or psychopharmacology that accounts for most of the magical transformation that happens in our office. It is the quality of the relationships that we build with our clients. All we have to do is confirm the gravity of this truth is to think back upon a time in our own lives when we navigated through emotional difficulty and we'll see that it was the support, care, and presence of another that we recall as the active ingredient in our own successful resolution of this problem.

After fully integrating the work of Hubble, Duncan & Miller, I started seeing that there were **three** "active ingredients" to successful resolution of traumatic stress symptoms— relationship, relaxation, and narratives. Without the relationship developed and maintained, I found that I was unable to successfully teach self-regulation or co- construct narratives with my trauma survivor clients. Since that time, I have treated thousands of people suffering the effects of traumatic stress. I have found that when we complete these three simple (not easy) therapeutic tasks, then my clients no longer meet diagnostic criteria for PTSD. And, unless they have some organic condition, when they complete these tasks they no longer meet diagnostic criteria for *any* Axis I or II condition.

Build and maintain a strong therapeutic relationship; teach survivors how to relax their bodies, especially in the context of a perceived threat; and help them construct complete chronological narratives of their traumatic experiences. The completion of these three tasks will heal traumatic stress. Three tasks = Trauma healed. Simple. Not easy but simple. Sometimes it takes years of work through countless sessions to complete these tasks. However, as a professional caregiver helping clients heal from traumatic stress, I am always working on one of these three tasks. I hope that I will be able to convince you, during today's session, of the value in this approach and why a clinician should avoid cognitive work with a trauma survivor. Either way, I suspect we're in for an exciting training.

Biographical J. Eric Gentry, PhD, LMHC is an internationally-recognized leader in the field of disaster and clinical traumatology. His doctorate is from Florida State University where he studied with Professor Charles Figley, one of the pioneers of traumatic stress. Dr. Gentry was one of the original faculty members of the Traumatology Institute and later became the co-director of the International Traumatology Institute at the University of South Florida. Dr. Gentry, along with Dr. Anna Baranowsky, is the co-author and co- owner of the Traumatology Institute Training Curriculum—17 courses in field and clinical traumatology leading to seven separate certifications. He has trained thousands of professionals and paraprofessionals worldwide in the treatment of traumatic stress. He has been a clinical member of several CISM teams and has provided assistance in many different disaster and critical incidents including Oklahoma City, New York City, and hurricanes in Florida. He was the developer of the Community Crisis Support Team, which began in Tampa, Florida and has become a model for

communities to integrate mental health services into their disaster response network. Dr. Gentry has published many research articles, book chapters, and periodicals in this maturing area of study. He is the co-author of *Trauma Practice: Tools for Stabilization and Recovery* published by Hogrefe and Huber in 2004 (2011; 2013) and *Forward-Facing Trauma Therapy* in 2016. He has a private clinical and consulting practice in Sarasota, FL and is adjunct faculty at many universities. Dr. Gentry draws equally from his scientific study and from his rich history of 35 years of professional care giving to balance this training with current, empirically-grounded information and experienced-based compassionate intervention skills. You will be challenged, inspired, and uplifted by Dr. Gentry and this unique day of training.




Healing Trauma

Simple....not easy

COURSE OUTLINE **1. PREPARATION & RELATIONSHIP** FOUNDATIONAL ISSUES IN ADDICTIONS-INFORMED **PSYCHOTHERAPY** Assessment ADDICTION VS. SUBSTANCE USE DISORDER VS. Feedback Informed Tx CHEMICAL DEPENDENCE 2. SKILLS DEVELOPMENT & COGNITIVE RESTRUCTURING NEUROBIOLOGY OF ADDICTION Tools for Hope/ANS CAUSES OF ADDICTION (BIOPSYCHOSOCIAL) • Self-Regulation ATTACHMENT ISSUES Graphic Time-Line/Narrative • TRAUMATIC STRESS Shame > Self-Compassion Additional Stabilization & Containment WHAT CAUSES TRAUMA? **3. DESENSITIZATION & INTEGRATION** SYMPTOMS OF PTS(D) In vivo Exposure **EMPOWERMENT & RESILIENCE TREATMENT** Forward-Facing® Trauma Therapy STRUCTURE: FOUR-STAGE BEHAVIORAL TREATMENT MODEL FOR CO-OCCURRING TRAUMATIC STRESS Capacity-Building AND ADDICTION Imaginal Exposure (1+ year of recovery) PREPARATION & RELATIONSHIP 4. POSTTRAUMATIC GROWTH & RESILIENCE **SKILLS DEVELOPMENT & COGNITIVE** 2. Elements of PTG RESTRUCTURING Continuance of IVE/FFTT/Capacity-**DESENSITIZATION & INTEGRATION** 3. Building

- 4. POSTTRAUMATIC GROWTH & RESILIENCE
- Reconnection
- Optimization
- OBJECTIVES CONCEPTUALIZE IMPORTANCE OF TEACHING CLIENTS SUMMARIZE THE CAUSES OF SUBSTANCE USE 8. 1. ABOUT ANS FUNCTIONS ESPECIALLY THREAT RESPONSE DISORDERS & FACTORS THAT REINFORCE DRUG (TOOLS FOR HOPE) USE AS RELATED TO CASE CONCEPTUALIZATION. IDENTIFY THE KEY COMPONENTS TO INTERRUPTING EXPLAIN THE BASIC NEUROBIOLOGY OF 9. 2. THREAT RESPONSE IN REAL-TIME ACTIVITIES (SELF-ADDICTIVE CHEMICALS AND ITS TREATMENT REGULATION) IMPLICATIONS. 10. DEVELOP SKILLS FOR AMELIORATING SHAME TOWARDS CONCEPTUALIZE TREATMENT THAT ADDRESSES 3. SELF-COMPASSION USING GRAPHIC TIME LINE **BOTH TRAUMATIC STRESS AND ADDICTION** INTERVENTION CONCURRENTLY SKILLS DEVELOPMENT FOR RELAXATION, GROUNDING & 11. DISCOVER THE "ACTIVE INGREDIENTS" FOR 4. CONTAINMENT TO ASSIST WITH SAFETY & TRAUMA TREATMENT THAT WORK EQUALLY WELL STABILIZATION WITH ADDICTIVE DISORDERS 12. EMPLOY PRINCIPLES OF RECIPROCAL INHIBITION TO 5. DEVELOP SKILLS FOR ASSESSING TRAUMATIC ENGAGE IN VIVO EXPOSURE TO LESSEN PTS(D) AND ADDICTION SX STRESS & ADDICTION DISORDERS LEARN FORWARD-FACING® TRAUMA THERAPY COMPETENTLY IMPLEMENT FEEDBACK INFORMED 13. 6. THERAPY WITH TRAUMADDICTED CLIENTS LEARN AND IMPLEMENT INTO PRACTICE CAPACITY-14. FOLLOWING TRAINING TO DEVELOP, MAINTAIN & BUILDING AS SKILLS DEVELOPMENT AND TRAUMA 🔘 ENHANCE THERAPEUTIC RELATIONSHIP AND RESOLUTION POSITIVE OUTCOMES DISCOVER PRINCIPLES OF POSTTRAUMATIC GROWTH 15. DISCOVER TECHNICAL AND RELATIONAL 7. AND RESILIENCE FOR BOTH EARLY-STAGE INTERVENTIONS FOR ENHANCING POSITIVE SKILLSOBUILDING LATER-STAGE OPTIMIZATION EXPECTANCY DURING TREATMENT







APA CEU STATEMENT

MATERIALS THAT ARE INCLUDED IN THIS COURSE MAY INCLUDE INTERVENTIONS AND MODALITIES THAT ARE BEYOND THE AUTHORIZED PRACTICE OF MENTAL HEALTH PROFESSIONALS. AS A LICENSED PROFESSIONAL, YOU ARE RESPONSIBLE FOR REVIEWING THE SCOPE OF PRACTICE, INCLUDING ACTIVITIES THAT ARE DEFINED IN LAW AS BEYOND THE BOUNDARIES OF PRACTICE IN ACCORDANCE WITH AND IN COMPLIANCE WITH YOUR PROFESSIONAL STANDARDS

ERIC'S CEU STATEMENT

- 250+ CITATIONS FOR THIS COURSE
- BOARD-CERTIFIED EXPERT IN TRAUMATIC STRESS (2008)/CERTIFIED ADDICTIONS COUNSELOR (1993)
- 37 YEARS OF CLINICAL EXPERIENCE WITH TRAUMA AND ADDICTION
- 25 YEARS CLEAN (32 YEARS IN RECOVERY) STILL REGULARLY ATTEND MEETINGS OF A 12-STEP FELLOWSHIP
- BALANCE OF SCIENCE AND LITERATURE-BASED INTERVENTIONS WITH PRACTICAL RELATIONAL-BASED DELIVERY

4

ERIC'S BIASES

- ANXIETY/STRESS IS A THREAT RESPONSE. IT IS THIS THREAT RESPONSE THAT PRODUCES ALL OUR CLIENT'S DISTRESS (UNLESS ORGANICITY). MUCH OF THIS COURSE IS ORGANIZED AROUND TEACHING CLINICIANS TO INTERRUPT THEIR OWN THREAT RESPONSES AND THEN TEACHING CLIENTS THE SAME. YOU CANNOT HAVE STRESS IN A RELAXED BODY
- EVIDENCE-BASED TREATMENTS DO NOT RESOLVE TRAUMA OR ADDICTION -THE EFFECTIVE DELIVERY OF THESE TREATMENTS BY RELATIONALLY & TECHNICALLY PROFICIENT PRACTITIONERS DO.
- ADDICTION IS A SOLUTION—ALBEIT WITH DIMINISHING EFFECTIVENESS— FOR SURVIVORS OF TRAUMA AND THEIR CHRONICALLY DYSREGULATED ANS...A SOLUTION THAT BECOMES THE PROBLEM. ALTHOUGH PROGRESSIVE, INCURABLE AND FATAL, IT CAN BE ARRESTED AND RECOVERY IS POSSIBLE
- TRAUMA ALMOST ALWAYS HAS CONCOMITANT ADDICTION COMPONENT AND ADDICTION ALMOST ALWAYS HAS A TRAUMATIC STRESS COMPONENT - THEY SHOULD BE TREATED SIMULTANEOUSLY

5

COURSE OUTLINE

- FOUNDATIONAL ISSUES IN ADDICTIONS-INFORMED PSYCHOTHERAPY
- ADDICTION VS. SUBSTANCE USE DISORDER VS.
- CHEMICAL DEPENDENCE
- NEUROBIOLOGY OF ADDICTION CAUSES OF ADDICTION (BIOPSYCHOSOCIAL)
- ATTACHMENT ISSUES
- RAUMATIC STRESS
- WHAT CAUSES TRAUMA?
- SYMPTOMS OF PTS(D) MPOWERMENT & RESILIENCE TREATMENT
- STRUCTURE: FOUR-STAGE BEHAVIORAL TREATMENT MODEL FOR CO-OCCURRING TRAUMATIC STRESS ND ADDICTION
- PREPARATION & RELATIONSHIP
- SKILLS DEVELOPMENT & COGNITIVE RESTRUCTURING
- DESENSITIZATION & INTEGRATION
- POSTTRAUMATIC GROWTH & RESILIENCE
- 6

2. SKILLS DEVELOPMENT & COGNITIVE RESTRUCTURING Tools for Hope/ANSSelf-Regulation

1. PREPARATION & RELATIONSHIP

AssessmentFeedback Informed Tx

- Graphic Time-Line/Narrative
 Shame > Self-Compassion
 Additional Stabilization & Containment
 J. DESENSITIZATION & INTEGRATION
 - In vivo ExposureForward-Facing® Trauma Therapy Capacity-Building Imaginal Exposure (1+ year of
- 4. POSTTRAUMATIC GROWTH & RESILIENCE · Elements of PTG . Continuance of IVE/FFTT/Capacity-
- Building Reconnection

OBJECTIVES

8.

10.

SUMMARIZE THE CAUSES OF SUBSTANCE USE DISORDERS & FACTORS THAT REINFORCE DRUG

0

- EXPLAIN THE BASIC NEUROBIOLOGY OF ADDICTIVE CHEMICALS AND ITS TREATMENT IMPLICATIONS. 2.
- CONCEPTUALIZE TREATMENT THAT ADDRESSES BOTH TRAUMATIC STRESS AND ADDICTION з.
- CONCURRENTLY DISCOVER THE "ACTIVE INGREDIENTS" FOR TRAUMA TREATMENT THAT WORK EQUALLY WELL WITH ADDICTIVE DISORDERS 12.
- DEVELOP SKILLS FOR ASSESSING TRAUMATIC 5
- STRESS & ADDICTION DISORDERS
- THERAPY WITH TRAUMADDICTED CLIENTS FOLLOWING TRAINING TO DEVELOP, MAINTAIN & ENHANCE THERAPEUTIC RELATIONSHIP AND POSITIVE OUTCOMES 15.
- DISCOVER TECHNICAL AND RELATIONAL INTERVENTIONS FOR ENHANCING POSITIVE EXPECTANCY DURING TREATMENT
- 7

- CONCEPTUALIZE IMPORTANCE OF TEACHING CLIENTS ABOUT ANS FUNCTIONS ESPECIALLY THREAT RESPONSE (TOOLS FOR HOPE)
- IDENTIFY THE KEY COMPONENTS TO INTERRUPTING THREAT RESPONSE IN REAL-TIME ACTIVITIES (SELF-REGULATION)
- DEVELOP SKILLS FOR AMELIORATING SHAME TOWARDS SELF-COMPASSION USING GRAPHIC TIME LINE INTERVENTION
- 11. SKILLS DEVELOPMENT FOR RELAXATION, GROUNDING & CONTAINMENT TO ASSIST WITH SAFETY & L STABILIZATION
- 12. EMPLOY PRINCIPLES OF RECIPROCAL INHIBITION TO ENGAGE IN VIVO EXPOSURE TO LESSEN PTS(D) AND ADDICTION SX
- COMPETENTLY IMPLEMENT FEEDBACK INFORMED 13. LEARN FORWARD-FACING® TRAUMA THERAPY
 - LEARN AND IMPLEMENT INTO PRACTICE CAPACITY-BUILDING AS SKILLS DEVELOPMENT AND TRAUMA RESOLUTION
 - 15. DISCOVER PRINCIPLES OF POSTTRAUMATIC GROWTH AND RESILIENCE FOR BOTH EARLY-STAGE SKILLSOBUILDING LATER-STAGE OPTIMIZATION

0



8

TRAUMADDICTION

- · 35% TO 50% OF PEOPLE IN ADDICTION TREATMENT PROGRAMS HAVE A LIFETIME DIAGNOSIS OF POSTTRAUMATIC STRESS DISORDER (PTSD)
- · 25% TO 42% HAVE A CURRENT DIAGNOSIS OF PTSD
- CO-OCCURRING PTSD AND SUBSTANCE USE DISORDERS ADD TO GREATER PROBLEM SEVERITY IN PSYCHIATRIC, MEDICAL, SOCIAL AND EMPLOYMENT FUNCTIONING
- PERSONS WITH PTSD RESPOND LESS FAVORABLY TO ROUTINE TREATMENTS, USE MORE TREATMENT SERVICES, ARE MORE LIKELY TO DROP OUT OF TREATMENT, AND ARE LESS LIKELY TO REMAIN IN CONTINUING CARE.
- HISTORICALLY, ADDICTION TREATMENT PROGRAMS DID NOT ADDRESS PTSD FOR FEAR OF STIMULATING OR EXACERBATING RE-EXPERIENCING SYMPTOMS (NIGHTMARES, FLASHBACKS, RE-LIVING TRAUMATIC EVENTS), AND RISK JEOPARDIZING EARLY AND UNSTABLE PERIODS OF ABSTINENCE (KILLEEN ET AL., 2008).
- (Back et al., 2000), Brady, Back, & Coffer, 2004; P. Livern, Resupera, & Start, 1995; Caccious, Alemman, McKary, & Rutherford, 2001; Daniky et al., 1996; Jacobsen, Southvick, & Kosten, 2001; Milli, Lynikey, Teesson, Ross, & Darke, 2005; Ouimette, Ahren, Moos, & Finney, 1997; Trafton et al.,


TRAUMATIC STRESS & ADDICTION

- ARE BOTH THE AFTEREFFECTS OF TRAUMA
- BOTH ARE CAUSES BY DYSREGULATION OF THE ANS (DYSAUTONOMIA)
- BOTH ARE DEBILITATING, MISUNDERSTOOD, PROGRESSIVE, AND FATAL
- ARE BOTH ARRESTED WITH THE INTERRUPTION OF THE THREAT RESPONSE/SELF-REGULATION & CONNECTION
- SHOULD BE TREATED CONCURRENTLY


10



11











0 APA: ADDICTION IS A COMPLEX CONDITION A BRAIN DISEASE THAT IS MANIFESTED BY COMPULSIVE SUBSTANCE USE DESPITE HARMFUL CONSEQUENCE. PEOPLE WITH AMERICAN ADDICTION (SEVERE SUBSTANCE USE DISORDER) HAVE AN INTENSE FOCUS ON USING A CERTAIN SUBSTANCE(S), **PSYCHIATRIC** SUCH AS ALCOHOL OR DRUGS, TO THE POINT THAT IT ASSOCIATION TAKES OVER THEIR LIFE. DSM 5 - SUBSTANCE-USE DISORDERS: ARE PATTERNS OF SYMPTOMS RESULTING FROM THE USE OF A SUBSTANCE nFPS THAT YOU CONTINUE TO TAKE, DESPITE EXPERIENCING DSM-5 PROBLEMS AS A RESULT. DSM 5 - SUBSTANCE-INDUCED DISORDERS, INCLUDING INTOXICATION, WITHDRAWAL, AND OTHER SUBSTANCE/MEDICATION-INDUCED MENTAL DISORDERS, ARE DETAILED ALONGSIDE SUBSTANCE USE DISORDERS. ٢

14












Criterion	DSM-IV substance dependence	DSM-5 substance us disorder
Tolerance	√	√
Withdrawal	\checkmark	\checkmark
Taken more/longer than intended	\checkmark	\checkmark
Desire/unsuccessful efforts to quit use	\checkmark	\checkmark
Great deal of time taken by activities involved in use	\checkmark	✓
Use despite knowledge of problems associated with use	~	✓
Important activities given up because of use	~	\checkmark
Recurrent use resulting in a failure to fulfill important role obligations		~
Recurrent use resulting in physically hazardous behavior (e.g., driving)		~
Continued use despite recurrent social problems associated with use		\checkmark









SUBSTANCE USE DISORDER

	SUBSTANCE USE DISORDER IN DISM'S COMBINES THE DISM'L CATECORES OF SUBSTANCE AURSE AND SUBSTANCE DIPERDINCE INFO A SINGEL DISORDER MEASURED ON A CONTINUUM FROM MUID TO SUVERE. LACH SPECIFIC SUBSTANCE USE DISORDER) IS ADDRESSED AS A SERVARU EUS DISORDER SA SUBSTANCE USE DISORDER IS ADDRESSED AS A SERVARU EUS DISORDER (E.G., ALCONOLUE DISORDER, DISMILIANTI USE DISORDER (E.G., LUCIONI, USE DISORDER, JUNICATIONE DISORDER, FLC, BUT HARVY ALL SUBSTANCES ARE DIACHOSED BASED ON THE SAME OVERACHING CITERAL. IN THIS OVERACHING DISORDER, THE CITERA HARV FOIL ON VERNI COMBINED, BUT STEINGTHERED, WHEREA A DUCHOSED SE SUBSTANCE BASIS PROVIDUSY REQUIRES TWO TO DIHEE STANTON, MUID SUBSTANCE USE DISORDER IN DISA. BEQUIRES TWO TO THE SERVATIONS FROM A LIST OF 11. DISUE CORMING WILL & BEDINATED TO THE UST AND FOOLISMS WITH ANY REVORCHNET WILL BE EXIMATED TO THE DISORDER FLOX. DISORDER FLOXED THAT MARKE THE CRITERIA DIRACIDIES TO THE CONSTRUCTION ON DISORDERATIONS THAT MARKE THE CRITERIA DIRACIDIES TO THE DISORDER IN DISA. SERVICES DISORDER IN DISA. BECOMEST TWO TO THE STANTON AND SUBSTANCE USE DISORDER IN DISA. BERDINEST TWO TO THE STANTON AND SUBSTANCE USE DISORDER IN DISA. BERDINEST TWO TO THE STANTON AND SUBSTANCE USE DISORDER IN DISA. BERDINEST TWO TO THE STANTON AND SUBSTANCE USE DISORDER IN DISA. BERDINEST TWO TO THE STANTON AND SUBSTANCE USE DISORDER IN DISA. BERDINEST TWO TO THE STANTON AND SUBSTANCE USE DISORDER IN DISA. BERDINEST TWO TO THE STANTON AND SUBSTANT ON A DIST OF THIS DIST. AND THE STANTON THAT AND REDIRATIONS TO A LIST OF THIS DIST. AND THE PE CRITERIA DIST.
SUBSTANCE USE DISORDER	 IN DSM-IV, THE DISTINCTION BETWEEN ABUSE AND DEPENDENCE WAS BASED ON THE CONCEPT OF ABUSE AS A MUD OF EARLY PHASE AND DEPENDENCE AS THE MORE SERVISE MAINTESTATION IN PRACTICE, THE ABUSE CRITERIA WEER SOMETIMES QUITE SEVERE. THE REVISED SUBSTANCE USE DISORDER, A SINGLE DUCAROSS, WILL BETTR MATCH THE STIMPTOMS THAT PATIENTS EXPERIENCE. ADDITIONALLY, THE DUCAROSS OF DEPENDENCE CAUSED MUCH CONFUSION. MOST PROFILE LINK DEPENDENCE WITH "ADDICTION" WHEN IN FACT DEPENDENCE CAN BE A NORMAL BODY RESPONSE TO A SUBSTANCE.

22

ADDICTIVE DISORDERS

	 THE CHAPTER ALSO INCLUDES GANBING DISORDER AS THE SOLE CONDITION IN A NEW CAREGORY ON BEHAVIORAL ADDICTIONS. DSM./V LISTED PATHOLOGICAL GANBING BUT IN A DIFFERENT CHAPTER. THIS NEW TERM AND ISI GOLATION IN THE NEW MANULA REFLECT RESEARCH FINDINGS THAT GAMBING DISORDER IS SIMILAR TO SUBSTANCE-RELATED DISORDERS IN CLINCAL EXPRESSION, BRAIN ORIGIN, COMORBIDITY, PHYSIOLOGY, AND TERATMENT.
	RECOGNITION OF THESE COMMONALITIES WILL HELP PEOPLE WITH GAMBING DISORDER GET THE TREATMENT AND SERVICES THE'N NEED, AND OTHESE ANY BETTER UNDERSTAND THE CHALLENGES THAT INDIVIDUALS FACE IN OVERCOM- ING THIS DISORDER.
ADDICTIVE DISORDERS	• WHLE GAMELING DISOPPER IS THE ONLY ADDICITIVE DISORDER INCLUDED IN DSM-5 AS A DIAGNOSABLE CONDITION, INTERET GAMING DISORDER WILL BE INCLUDED IN SECTION III OF THE ANNAL. DISORDERS IISTED THERE REQUIRE PURTHER RESARCH BEFORE THER CONDIDENTION AS FORMAL DISORDERS. THIS CONDITION IS INCLUDED TO REFLECT THE SCIENTIFIC LITERATURE ON PERSISTENT AND RECURRENT USE OF INTERNET GAMES, AND A PEROCUMPTION WITH THEM, CAN ESSUIT IN CUINCALLY SIGNIFICANT IMAILMENT OR DISTERSS. MUCH OF THIS LITERATURE COMES FROM STUDIES IN ASAN COUNTRES. THE CONDITION CRITERED DO NOT INCLUDE COMERAL USE OF THE INTERNET, GAMBLING, OR SOCIAL MEDIA AT THIS TIME.

2013, American Psychiatric Association

23

NARCOTICS ANONYMOUS


AS ADDICTS, WE HAVE AN INCURABLE DISEASE CALLED ADDICTION. THE DISEASE IS CHRONIC, PROCRESSIVE AND FATAL HOWEVER, IT IS A TREATABLE DISEASE. WE FEL THAT EACH INDIVIDUAL HAS TO ANAVER THE QUESTION, "ANI AN ADDICT" HOW WE GOT THE DISEASE IS OF NO INMEDIATE IMPORTANCE TO US. WE ARE CONCERNED WITH RECOVERY.

 NARCOTICS ANONYMOUS FELLOWSHP, NARCOTICS ANONYMOUS . LIBRE DIGITAL KINDLE EDITION.





The physical aspect of our disease is the compulsive use of drugs: the inability to stop using once we have started. The mental aspect of our disease is the obsession, or overpowering desire to use, even when we are destroying our lives. The spiritual part of our disease is our total self-centeredness.

Narcotics Anonymous Fellowship, Narcotics Anonymous , Lib Digital, Kindle Edition.












KEY FINDINGS*


- WELL-SUPPORTED SCIENTIFIC EVIDENCE SHOWS THAT ADDICTION TO ALCOHOL OR DRUGS IS A CHRONIC BRAIN DISEASE THAT HAS POTENTIAL FOR RECURRENCE AND RECOVERY.
- WELL-SUPPORTED EVIDENCE SUGGESTS THAT THE ADDICTION PROCESS INVOLVES A THRE-STAGE CYCLE: BINGE/ INTOXICATION, WITHDRAWAL/NEGATIVE AFFECT, AND PREOCCUPATION/ANTICIPATION. THIS CYCLE BECOMES MORE SEVERE AS A PERSON CONTINUES SUBSTANCE USE AND AS IT PRODUCES DRAWATIC CHANGES IN BRAIN FUNCTION THAT REDUCE A PERSON'S ABILITY TO CONTROL HIS OR HER SUBSTANCE USE.
- WELL-SUPPORTED SCIENTIFIC EVIDENCE SHOWS THAT DISRUPTIONS IN THREE AREAS OF THE BRAIN ARE PARTICULARLY IMPORTANT IN THE ONSET, DEVELOPMENT, AND MAINTENANCE OF SUBSTANCE USE DISORDERS: THE BASAL GANCILA, THE EXTENDED ANYODALA, AND THE PREFENCENTAL CORTEX. THESE DISRUPTIONS. (1) ENABLE SUBSTANCE-ASSOCIATED CUES TO TRIGGER SUBSTANCE SEEKING (ILE, THEY INCREASE INCENTIVE SALEINCE); (2) REDUCE SENSITIVITY OF BRAIN SYSTEMS INVOLVED IN THE EXPERIENCE OF PLEASURE OR ERWARD, AND HEGHTEN ACTIVATION OF BRAIN STRESS SYSTEMS; AND (3) REDUCE FUNCTIONING OF BRAIN EXECUTIVE CONTROL SYSTEMS, WHICH ARE INVOLVED IN THE ABILITY TO MARE DECISIONS AND REGULATE ONE'S ACTIONS, ENOTIONS, AND IMPULSES.
- SUPPORTED SCIENTIFIC EVIDENCE SHOWS THAT THESE CHANGES IN THE BRAIN PERSIST LONG AFTER SUBSTANCE USE STOPS. IT IS NOT YET KNOWN HOW MUCH THESE CHANGES MAY BE REVERSED OR HOW LONG THAT PROCESS MAY TAKE.
- WELL-SUPPORTED SCIENTIFIC EVIDENCE SHOWS THAT ADOLESCENCE IS A CRITICAL "AT-RISK PERIOD" FOR SUBSTANCE USE AND ADDICTION. ALL ADDICTIVE DRUGS, INCLUDING ALCOHOL AND MARIUANA, HAVE ESPECIALLY HARMFUL EFFECTS ON THE ADOLESCENT BRAIN, WHICH IS STILL UNDERGOING SIGNIFICANT DEVELOPMENT.
- * WELL-SUPPORTED. WHEN EVIDENCE IS DERIVED FROM MULTIPLE RIGOROUS HUMAN AND NONHUMAN STUDIES; SUPPORTED. WHEN EVIDENCE IS DERIVED FROM RIGOROUS BUT EPV/EP HIMAN AND NONHI MAIN STUDIES.

28


- SUBSTANCE USE DISORDERS RESULT FROM CHANGES IN THE BRAIN THAT CAN OCCUR WITH REPEATED USE OF ALCOHOL OR DRUGS. THE MOST SEVERE EXPRESSION OF THE DISORDER, ADDICTION, IS ASSOCIATED WITH CHANGES IN THE FUNCTION OF BRAIN CIRCUITS INVOLVED IN PLEASURE (THE REWARD SYSTEM), LEARNING, STRESS, DECISION MAKING, AND SELF-CONTROL.
- EVERY SUBSTANCE HAS SLIGHTLY DIFFERENT EFFECTS ON THE BRAIN, BUT ALL ADDICTIVE DRUGS, INCLUDING ALCOHOL, OPIOIDS, AND COCAINE, PRODUCE A PLEASURABLE SURGE OF THE NEUROTRANSMITTER DOPAMINE IN A REGION OF THE BRAIN CALLED THE BASAL GANGLIA; NEUROTRANSMITTERS ARE CHEMICALS THAT TRANSMIT MESSAGES BETWEEN NERVE CELLS.
- THIS AREA IS RESPONSIBLE FOR CONTROLLING REWARD AND OUR
 ABILITY TO LEARN BASED ON REWARDS

29



























































































STRESS CAUSE AND EFFECT Vork Finances Health/COVID-19 News Family Relationships Demands




53








































What works?

AVAILABLE EVIDENCE DOCUMENTS THAT THE THERAPIST IS ONE OF THE MOST ROBUST PREDICTORS OF OUTCOME AMONG FACTORS STUDIED.

- THERAPISTS (5%-9%) IS LARGER THAN THE VARIABILITY OF
- TREATMENTS (0%-1%), THE
- ALLIANCE (5%), AND THE
- Superiority of an empirically supported treatment to a placebo treatment (0%–4%)

(DUNCAN ET AL., 2010; LUTZ ET AL., 2007; WAMPOLD, 2005).

64



65

ACTIVE INGREDIENTS APPROACH


- BENISH, IMEL & WAMPOLD (2008)
- GENTRY, 1999
- GENTRY, BARANOWSKY & RHOTON (2017)
- NATIONAL CENTER FOR PTSD/VA/DOD (2010; 2012; 2016)
- CLOITRE, COURTOIS, CHARUVASTRA, CARAPEZZA, STOLBACH, GREEN (2011)
- SCHNYDER, EHLERS, ELBERT, FOA, GERSONS, RESICK, ... CLOITRE (2015)
- MURRAY, ET AL.,2015




CHANGING THE PARADIGM

NETWORK NETWORK PSYCHOTHERAPY HAS BEEN FOLIND TO BE AN EFFECTIVE TREATMENT OF POST-TRAUMATIC STRESS DISORDER (PSO), BUT WETAWAUKYSS HAVE YELDED INCONSISTENT REJULTS ON RELATIVE EFFICACY OF PSYCHOTHERAPYES IN THE TREATMENT OF PISD. THE PRESENT WETA-ANALYSIS CONTROLLED FOR POTENTIAL CONFOLINGS IN PREVIOUS PTSD META-ANALYSES BY NOLDING ONLY BOAN AFDE PSYCHOTHERAPES, ANDIDING CATEGORIZATION OF PSYCHOTHERAPYES IN THE TREATMENT, AND USING DIRECT COMMRISON STUDIES ONLY THE PRIMARY ANALYSIS REVEALED THAT EFFECT SIZES WERE HOMOGENOUSLY DISTRIBUTED AROUND ZERO FOR MEASURES OF PTSD SYMPTOMOLOGY, AND FOR ALL MEASURES OF PSYCHOLOGICAL FUNCTIONING, INDICATING THAT THERE WERE IND DIFFERENCES BETWEEN PSYCHOTHERAPIES, ADDITIONALLY, THE UPPER BOUND OF THE TREE FFECT SIZE BETWEEN PTSD PSYCHOTHERAPES WAS QUITE SMALL THE RESULTS SUGGEST THAT DESMITE STRONG RUBBERG OF PSYCHOTHERAPES WAS QUITE SMALL THE RESULTS SUGGEST THAT DESMITE STRONG RUBBERG OF PSYCHOTHERAPES WAS QUITE SMALL THE RESULTS BUGGEST THAT DESMITE STRONG RUBBERG OF PSYCHOTHERAPES PRODUCE EQUIVALENT BENETS FOR MIDENTS WITH IPSD.

67







HEALING TRAUMA: ACTIVE INGREDIENTS

(GENTRY, 1999; GENTRY, BARANOWSKY & RHOTON, 2017)

THERAPEUTIC RELATIONSHIP

• RELAXATION/SELF-REGULATION

EXPOSURE


• COGNITIVE RESTRUCTURING/


PSYCHOEDUCATION

70



71





73



- I. PREPARATION & RELATIONSHIP
- **II. PSYCHO-EDUCATION & SKILLS-**BUILDING
- **III. INTEGRATION & DESENSITIZATION**
- **IV. POST TRAUMATIC GROWTH &** RESILIENCE

RHOTON & GENTRY, 2014; 2019

74



- I. PREPARATION & RELATIONSHIP
- **PRE-SESSION INTENTION DELIBERATE PRACTICE** .
- ASSESSMENT (INSTRUMENTS & INTERVIEW) • INFORMED CONSENT (DOCUMENT & PROCESS)
- R-I-C-H •
- •
- EXPECTANCY (HOPE) BUILDING BEGIN COGNITIVE RESTRUCTURING (SURVIVAL = RESILIENCE) •
- LONGITUDINAL VS. CROSS-SECTIONAL VIEW
- BEGIN FEEDBACK-INFORMED THERAPY (MILLER, 2008) •
- DOWNWARD-MOVING SCORES ON THE SRS > STAGE II

Unless Survivor needs Stabilization; then implement skills training





- EXPLORE SUCCESS AND SHORTCOMINGS IN EARLY PART OF SESSIONS
- FORWARD-FACING® TRAUMA THERAPY [OPTIONAL] MID-SESSION ASSESSMENT (CRITERION B)
- IMAGINAL EXPOSURE METHODS (EBTS)
 - EMDR (PRIMARY)
- . HYPNOSIS (LESS AROUSAL)
- NARRATIVE METHODS (CPT/PE) LESS INDICATED .
- . IFS OR DISSOCIATIVE TABLE FOR DISSOCIAITON
- SE OR SENSIOMOTOR FOR SOMATIZATION
- MOURNING/GRIEF WORK

77

The Empowerment & Resilience Structure: An Active Ingredients Approach

IV: POSTTRAUMATIC GROWTH & RESILIENCE

- **MORE PRESENT & FUTURE FOCUSED** •
- **OPTIMIZATION VS. SYMPTOM REDUCTION**
- . CONSOLIDATING GAINS
- **REACTIVITY > INTENTIONALITY**
- . REPAIR MORAL WOUNDING
- **RELATIONAL ENGAGEMENT**
- CAM
- PTG PRINCIPLES .
- FFTT
- TERMINATION VS. LIFE-LONG CONSULTANT






POSITIVE EXPECTANCY/PLACEBO HOPE

- POWERFUL PREDICTOR OF POSITIVE OUTCOMES IN MULTIPLE METANALYTIC STUDIES
- NECESSARY BUT INSUFFICIENT FOR CHANGE
- CATALYZING EXPECTANCY IMPROVES EFFICACY OF INTERVENTION
- INCREASES ENGAGEMENT
- INCREASED CONTINUATION
- HOW DO YOU GET HOPE INTO THE HOPELESS
 - TECHNICAL MI
 - TRANSPERSONAL FELT-SENSE BY CLIENT THAT HELPER BELIEVES IN THEM AND THEIR PATH OF HEALING. SURETY.








Between stimulus and response there is a space. In that space is our power to choose our response. In our response lies our growth and our freedom.

- Viktor Frank

82



83

FEEDBACK INFORMED THERAPY (MILLER, 2008)

• EBT IN 2013.

- +25K DATA POINTS OF EFFECTIVENESS
- SCORES OF STUDIES; MULTIPLE RCTS
- ONE OF THE MOST EFFECTIVE MODALITIES AVAILABLE IN
 PSYCHOTHERAPY—MODEL OF TREATMENT IS MUCH LESS RELEVANT
- NEAR 2X EFFECTIVENESS BY IMPLEMENTING FIT WITH WELL-DESIGNED STUDIES










86

SUGGESTIONS FOR POSITIVE OUTCOMES WWW.SCOTTDMILLER.COM


1. COLLECT EMPIRICAL DATA EVALUATING THE QUALITY OF THE THERAPEUTIC PROCESS & RELATIONSHIP

- 2. GENERATE HONEST FEEDBACK FROM CLIENT ON METHODS TO IMPROVE THERAPY (I.E. RELATIONAL)
- 3. BE WILLING TO CHANGE TOWARD WHAT WORKS BEST FOR CLIENT-DEMONSTRATE THAT CHANGE


















GRAPHIC TIME LINE


- USE PART 1 OF TRS
- 5 MIN ALL THE DIFFICULT/PAINFUL/TRAUMATIC EXPERIENCES
- 5 MIN ALL THE POSITIVE EXPERIENCES
- 30 MIN VERBAL NARRATIVE
- WARNING: INDICATED ONLY FOR CLIENT WHO ARE SAFE & STABLE.
 INTERMEDIATE SKILLS TRAINING BEFORE THIS INTERVENTION WITH
 THOSE NOT STABLE


92











95

COGNITIVE RESTRUCTURING

- WHAT WOULD ANY REASONABLE RATIONAL HUMAN BEING COME TO BELIEVE ABOUT THEMSELVES (INTELLECTUALLY, EMOTIONALLY, SPIRITUALLY, PSYCHOLOGICALLY, PHYSICALLY, SOCIALLY, AND ACADEMICALLY) FROM HAVING THESE THINGS OCCUR IN THEIR LIFE⁸
- WHAT WOULD ANY REASONABLE RATIONAL HUMAN BEING COME TO BELIEVE ABOUT IMPORTANT RELATIONSHIPS (INTELLECTUALLY, EMOTIONALLY, SPIRITUALLY, PSYCHOLOGICALLY, PHYSICALLY AND SOCIALLY) FROM HAVING THESE THINGS OCCUR IN THEIR LIFE?
- WHAT WOULD ANY REASONABLE RATIONAL HUMAN BEING COME TO BELIEVE ABOUT **THE WORLD AT LARGE** FROM HAVING THESE THINGS OCCUR IN THEIR LIFE?


EARLY SESSIONS


ACE – TRAUMA HISTORY

- TRS TRAUMA HISTORY & TX PLANNING
- PCL DIAGNOSIS
- BEGIN FEEDBACK INFORMED THERAPY (FIT)
- TOOLS FOR HOPE (PERCEIVED THREAT/ANS/SELF- REGULATION)
- PSYCHOEDUCATION (SHAME TO SELF-COMPASSION)
- GRAPHIC TIME LINE OF LIFE INCLUDING ALL SIGNIFICANT TRAUMATIC EXPERIENCES
- VERBAL NARRATIVE USING GTL AS MAP


BEGIN IN VIVO EXPOSURE WITH SELF-REGULATION





















ANCHORING - NLP

- DRAW PIX OF PLACE FROM HX OR IMAGINATION THAT IS SAFE & COMFORTABLE (5 MIN)
- "MAY I APPROACH YOU?"
- EXPERIMENT FLASHBACKS OF "GOOD" STUFF
- ANCHOR (SQUEEZE) STONE WHILE TELLING STORY
- CARRY STONE FOR WEEK
 - SQUEEZE WHEN ANXIOUS
 SQUEEZE WHEN COMFORTABLE
- REPORT NEXT WEEK
- 103























































The Empowerment & Resilience Structure: An Active Ingredients Approach III. INTEGRATION & DESENSITIZATION • IN VIVO PRACTICE • PERCEIVED THREATS + SELF REGULATION • EXPLORE SUCCESS AND SHORTCOMINGS IN EARLY PART OF SESSIONS • FORWARD-FACING® TRAUMA THERAPY • CAPACITY-BUILDING MID-SESSION ASSESSMENT (CRITERION B) • IMAGINAL EXPOSURE METHODS (EBTS) • EMDR • CPT/PE HYPNOSIS (LESS AROUSAL) • NARRATIVE METHODS • IFS OR DISSOCIATIVE TABLE FOR DISSOCIATION • SE OR SENSIONATOR FOR SOMATIZATION • SEO RESNSIONATOR FOR SOMATIZATION

116


























1. Brown RL, Rounds, LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wisconsin Medical Journal. 1995:94(3) 135-140.

STABLE	RESOL	RCF .	LUUI KI.	г

CAGE-AID Questionnaire

Patient	Name	
rauciii	Nume	

Date of Visit _____

When thinking about drug use, include illegal drug use and the use of prescription drug use other than prescribed.

Questions:	YES	NO
 Have you ever felt that you ought to cut down on your drinking or drug use? 		
2. Have people annoyed you by criticizing your drinking or drug use?		
3. Have you ever felt bad or guilty about your drinking or drug use?		
4. Have you ever had a drink or used drugs first thing in the morning to steady your nerves or to get rid of a hangover?		

Permission for use granted by Richard Brown, MD.



Am I an Addict? This is NA Fellowship-approved literature. Copyright © 1983, 1988 by

Narcotics Anonymous World Services, Inc. All rights reserved.

Only you can answer this question.

This may not be an easy thing to do. All through our usage, we told ourselves, "I can handle it." Even if this was true in the beginning, it is not so now. The drugs handled us. We lived to use and used to live. Very simply, an addict is a person whose life is controlled by drugs.

Perhaps you admit you have a problem with drugs, but you don't consider yourself an addict. All of us have preconceived ideas about what an addict is. There is nothing shameful about being an addict once you begin to take positive action. If you can identify with our problems, you may be able to identify with our solution. The following questions were written by recovering addicts in Narcotics Anonymous. If you have doubts about whether or not you're an addict, take a few moments to read the questions below and answer them as honestly as you can.

1.	Do you ever use alone?	Yes 🗖	No 🗖
2.	Have you ever substituted one drug for another, thinking that one particular drug was the problem?	Yes 🗋	No 🗖
3.	Have you ever manipulated or lied to a doctor to obtain prescription drugs?	Yes 🗋	No 🗖
4.	Have you ever stolen drugs or stolen to obtain drugs?	Yes 🗖	No 🗖
5.	Do you regularly use a drug when you wake up or when you go to bed?	Yes 🗖	No 🗖
6.	Have you ever taken one drug to overcome the effects of another?	Yes 🗖	No 🗖
7.	Do you avoid people or places that do not approve of you using drugs?	Yes 🗖	No 🗖
8.	Have you ever used a drug without knowing what it was or what it would do to you?	Yes 🗋	No 🗖
9.	Has your job or school performance ever suffered from the effects of your drug use?	Yes 🗖	No 🗖
10.	Have you ever been arrested as a result of using drugs?	Yes 🗖	No 🗖
11.	Have you ever lied about what or how much you use?	Yes 🗖	No 🗖
12.	Do you put the purchase of drugs ahead of your financial responsibilities?	Yes 🗖	No 🗖
13.	Have you ever tried to stop or control your using?	Yes 🗖	No 🗖
14.	Have you ever been in a jail, hospital, or drug rehabilitation center because of your using?	Yes 🗖	No 🗖
15.	Does using interfere with your sleeping or eating?	Yes 🗖	No 🗖

16	. Does the thought of running out of drugs terrify you?	Yes 🗖	No 🗖
17	. Do you feel it is impossible for you to live without drugs?	Yes 🗖	No 🗖
18	. Do you ever question your own sanity?	Yes 🗖	No 🗖
19	. Is your drug use making life at home unhappy?	Yes 🗖	No 🗖
20	. Have you ever thought you couldn't fit in or have a good time		
	without drugs?	Yes 🗖	No 🗖
21	. Have you ever felt defensive, guilty, or ashamed about your using?	Yes 🗖	No 🗖
22	. Do you think a lot about drugs?	Yes 🗖	No 🗖
23	. Have you had irrational or indefinable fears?	Yes 🗖	No 🗖
24	. Has using affected your sexual relationships?	Yes 🗖	No 🗖
25	. Have you ever taken drugs you didn't prefer?	Yes 🗖	No 🗖
26	. Have you ever used drugs because of emotional pain or stress?	Yes 🗖	No 🗖
27	. Have you ever overdosed on any drugs?	Yes 🗖	No 🗖
28	. Do you continue to use despite negative consequences?	Yes 🗖	No 🗖
29	. Do you think you might have a drug problem?	Yes 🗖	No 🗖

"Am I an addict?" This is a question only you can answer. We found that we all answered different numbers of these questions "Yes." The actual number of "Yes" responses wasn't as important as how we felt inside and how addiction had affected our lives.

Some of these questions don't even mention drugs. This is because addiction is an insidious disease that affects all areas of our lives—even those areas which seem at first to have little to do with drugs. The different drugs we used were not as important as why we used them and what they did to us.

When we first read these questions, it was frightening for us to think we might be addicts. Some of us tried to dismiss these thoughts by saying:

"Oh, those questions don't make sense;"

Or,

"I'm different. I know I take drugs, but I'm not an addict. I have real emotional/family/job problems;"

Or,

"I'm just having a tough time getting it together right now;"

Or,

"I'll be able to stop when I find the right person/get the right job, etc."

If you are an addict, you must first admit that you have a problem with drugs before any progress can be made toward recovery. These questions, when honestly approached, may help to show you how using drugs has made your life unmanageable. Addiction is a disease which, without recovery, ends in jails, institutions, and death. Many of us came to Narcotics Anonymous because drugs had stopped doing what we needed them to do. Addiction takes our pride, self-esteem, family, loved ones, and even our desire to live. If you have not reached this point in your addiction, you don't have to. We have found that our own private hell was within us. If you want help, you can find it in the Fellowship of Narcotics Anonymous.

"We were searching for an answer when we reached out and found Narcotics Anonymous. We came to our first NA meeting in defeat and didn't know what to expect. After sitting in a meeting, or several meetings, we began to feel that people cared and were willing to help. Although our minds told us that we would never make it, the people in the fellowship gave us hope by insisting that we could recover. [...] Surrounded by fellow addicts, we realized that we were not alone anymore. Recovery is what happens in our meetings. Our lives are at stake. We found that by putting recovery first, the program works. We faced three disturbing realizations:

- 1. We are powerless over addiction and our lives are unmanageable;
- 2. Although we are not responsible for our disease, we are responsible for our recovery;
- 3. We can no longer blame people, places, and things for our addiction. We must face our problems and our feelings.

The ultimate weapon for recovery is the recovering addict."

¹ Basic Text, Narcotics Anonymous

TRAUMA RE PART I Directions: Please read the following list and check Type Of Traumatic Event 1. Childhood Sexual Abuse 2. Rape 3. Other Adult Sexual Assault/Abuse 4. Natural Disaster 5. Industrial Disaster		Etes/Age(s)
Directions: Please read the following list and check Type Of Traumatic Event 1. Childhood Sexual Abuse 2. Rape 3. Other Adult Sexual Assault/Abuse 4. Natural Disaster		tes/Age(s)
Type Of Traumatic Event1.Childhood Sexual Abuse2.Rape3.Other Adult Sexual Assault/Abuse4.Natural Disaster		tes/Age(s)
 Childhood Sexual Abuse Rape Other Adult Sexual Assault/Abuse Natural Disaster 	Number of Times Dat	tes/Age(s)
 Rape Other Adult Sexual Assault/Abuse Natural Disaster 		
 Other Adult Sexual Assault/Abuse Natural Disaster 		
4. Natural Disaster		
Industrial Disaster		
6. Motor Vehicle Accident		
7 Combat Trauma		
8. Physical Injury/Medical		
9. Childhood Physical Abuse		
10. Adult Physical Abuse		
11. Victim Of Violent Crime		
12. Captivity		
13. Torture		
14. Domestic Violence		
15. Sexual Harassment		
16. Threat of physical violence		
17. Accidental physical injury		
18. Humiliation		
19. Property Loss		
20. Death Of Loved One 21. Neglect		
 Neglect Witnessed Event (see below) 		
23. Witnessed Event (see below) 24. Other:		
24. Other		
23. Other		

withesseu Event.	
Witnessed Event:	

PART II Place a mark on th	e line that best rep	presents your e	xperiences during	g the past week		
1. I make it through	ugh the day withou	ut distressing r	ecollections of pa	ast events.		
<u>.</u>	<u> </u>	<u>· · ·</u>	<u></u>	<u> </u>	of the time	
2. I sleep free fre	om nightmares.					
0%	· ·	· <u>·</u> ···	<u> </u>	<u>. </u>	f the time	
3. I am able to sta	ay in control when	n I think of diff	ficult memories.			
0%	<u> </u>	· <u>·</u> ····	<u> </u>	<u></u> 100% c	f the time	
4. I do the things thoughts of ev	s that I used to avo vents and people co	id (e.g., daily a connected with p	activities, social a past events).	activities,		
0%		<u>··</u>	<u>-</u>	<u> </u>	f the time	
5. I am safe.						<
0%	<u> </u>	<u> </u>	<u> </u>	<u>. </u>	f the time	\rightarrow
I feel safe.						
0%		· · · · ·		100% c	f the time	
6. I have support	-	n my life.				
0%	· · ·	··	**	<u></u> 100% c	f the time	
7. I find that I ca		a full range of				
0%	···	··	ii	<u>100</u> % c	f the time	
8. I can allow thin	ngs to happen in m		-			
0%	·····	· · · · ·	·····	100% c	f the time	
9. I am able to co	oncentrate on thou	ghts of my cho	pice.			
0%	<u> </u>	<u> </u>	<u> </u>	<u>. </u>	f the time	
10. I have a sense	of hope about the	future.				
0%	<u>·</u> _·	··	<u> </u>	<u> </u>	f the time	
AS – FS	falls on the line		score for where the has beside the item (avera and divide by 10.			Mean Score
	(significant reco	very/mild sympton oms); 74 (minimal	overy/subclinical); 8 ms); 75 – 85 (some r recovery/severe); bel	ecovery/		

Finding Y	our ACE Score
While you were growing up, during your first 1	8 years of life:
1. Did a parent or other adult in the household oft Swear at you, insult you, put you down, or	
or Act in a way that made you afraid that you Yes No	might be physically hurt? If yes enter 1
 Did a parent or other adult in the household oft Push, grab, slap, or throw something at yo or 	
Ever hit you so hard that you had marks o Yes No	r were injured? If yes enter 1
3. Did an adult or person at least 5 years older that Touch or fondle you or have you touch the	
or Attempt or actually have oral, anal, or vagi Yes No	nal intercourse with you? If yes enter 1
 Did you often or very often feel that No one in your family loved you or thought 	you were important or special?
or Your family didn't look out for each other, f Yes No	feel close to each other, or support each other? If yes enter 1
5. Did you often or very often feel that You didn't have enough to eat, had to wea or	r dirty clothes, and had no one to protect you?
	e care of you or take you to the doctor if you neede
Yes No	If yes enter 1
6. Were your parents ever separated or divorced? Yes No	If yes enter 1
7. Was your mother or stepmother: Often or very often pushed, grabbed, sla or	pped, or had something thrown at her?
Sometimes, often, or very often kicked,	bitten, hit with a fist, or hit with something hard?
or Ever repeatedly hit at least a few minutes Yes No	or threatened with a gun or knife? If yes enter 1
8. Did you live with anyone who was a problem dr Yes No	inker or alcoholic or who used street drugs? If yes enter 1
9. Was a household member depressed or menta Yes No	Ily ill, or did a household member attempt suicide? If yes enter 1
10. Did a household member go to prison? Yes No	If yes enter 1
Now add up your "Yes" answers:	This is your ACE Score.

DSM-V AND SUBSTANCE RELATED DISORDERS

The DSM-V combined the DSM-IV categories of substance dependence (addiction marked by a pattern of compulsive use or loss of control) and substance abuse disorders (using in a manner that causes problems but does not have a pattern of compulsive use) into one broad category of substance related disorder.

CLASSES:

The DSM-V recognizes substance related disorders resulting from the use of ten separate classes of drugs:

- 1. alcohol
- 2. caffeine
- 3. cannabis
- 4. hallucinogens (phencyclidine or similarly acting arylcyclohexylamines), other hallucinogens such as LSD
- 5. inhalants
- 6. opioids
- 7. sedatives
- 8. hypnotics
- 9. anxiolytics
- 10. stimulants (including amphetamine-type substances, cocaine, and other stimulants), tobacco, and
- 11. other or unknown substances.

Some major grouping of psychoactive substances are specifically identified. Use of other or unknown substances can also form the basis of a substance related or addictive disorder.

GROUPS:

There are two groups of substance-related disorders: substance use disorders and substance-induced disorders.

Substance use disorders are patterns of symptoms resulting from use of a substance which the individual continues to take, despite experiencing problems as a result.

Substance-induced disorders include intoxication, withdrawal, substance induced mental disorders, including substance induced psychosis, substance induced bipolar and related disorders, substance induced depressive disorders, substance induced anxiety disorders, substance induced obsessivecompulsive and related disorders, substance induced sleep disorders, substance induced sexual dysfunctions, substance induced delirium and substance induced neurocognitive disorders.

CRITERIA FOR SUBSTANCE USE DISORDER:

Substance use disorders span a wide variety of problems arising from substance use, and cover 11 different criteria:

- 1. Taking the substance in larger amounts or for longer than you meant to
- 2. Wanting to cut down or stop using the substance but not managing to
- 3. Spending a lot of time getting, using, or recovering from use of the substance
- 4. Cravings and urges to use the substance
- 5. Not managing to do what you should at work, home or school, because of substance use
- 6. Continuing to use, even when it causes problems in relationships
- 7. Giving up important social, occupational or recreational activities because of substance use
- 8. Using substances again and again, even when it puts you in danger
- 9. Continuing to use, even when you know you have a physical or psychological problem that could have been caused or made worse by the substance
- 10. Needing more of the substance to get the effect you want (tolerance)
- 11. Development of withdrawal symptoms, which can be relieved by taking more of the substance.

The DSM-V allows clinicians to specify how severe the substance use disorder is, depending on how many symptoms are identified:

MILD: Two or three symptoms indicate a mild substance use disorder.

MODERATE: Four or five symptoms indicate a moderate substance use disorder.

SEVERE: Six or more symptoms indicate a severe substance use disorder.

Clinicians can also add "in early remission," "in sustained remission," "on maintenance therapy," and "in a controlled environment."

	DSM-5 Su	DSM-5 Substance Use Diagnosis Guide	DMC Approved
DSM-5 DIAGNOSIS LABEL Atched Use Disorder, MILD Atchond Use Disorder, MILD Optiol Intoxication without Preceptual Disturbances with Use Disorder, MODERATE or SEVER Optiol Intoxication without Preceptual Disturbances with Use Disorder, MODERATE or SEVER Optiol Intoxication without Preceptual Disturbances with Use Disorder, MODERATE or SEVER Optiol Intoxication without Preceptual Disturbances with Use Disorder, MODERATE or SEVER Optiol Intoxication without Preceptual Disturbances with Use Disorder, MILD Cannable Use Disorder, MILD	EVERTY LEVELS		Billable Codes
	SUBSTANCE	DSM-5 DIAGNOSIS LABEL	ICD-10 CODES
			F10.10
	Alcoho	ol Use Disorder, MODERATE or SEVERE	F10.20
	1	ol Use Disorder, Mild in early or sustained REMISSION	F10.11
		ol Use Disorder, Moderate or Severe in early or sustained REMISSION	F10.21
		ol Intoxication with Use Disorder, MILD	F10.129
	Alcoho	ol Intoxication with Use Disorder, MODERATE or SEVERE	F10.229
	Alcoho	I Intoxication without Use Disorder	F10.929
	Alcoho	ol Withdrawal without Perceptual Disturbances	F10.239
		d Use Disorder, MILD	F11.10
		d Use Disorder, MODERATE or SEVERE	F11.20
		d Use Disorder, Mild in early or sustained REMISSION	F11.11
		d Use Disorder, Moderate or Severe in early or sustained REMISSION	F11.21
		i Intoxication without Perceptual Disturbances with Use Disorder, MILD	F11.129
		I Intoxication without Perceptual Disturbances with Use Disorder, MODERATE or SEVERE	F11.229
	Opioid	l Intoxication without Perceptual Disturbances without Use Disorder	F11.929
	Opioid	d Withdrawal	F11.23
	Cana	bis Hea Discorder Mil D	E12.10
			07:27 -
	Canna	bis Use Disorder, MODERATE or SEVERE	F12.20
		bis Use Disorder, Mild in early or sustained REMISSION	F12.11
		bis Use Disorder, Moderate or Severe in early or sustained REMISSION	F12.21
╶┶┫┠┵┶┶┶┶┹┫┠┶┵┷┶┶		bis Intoxication without Perceptual Disturbances with Use Disorder, MILD	F12.129
	Cannal	bis Intoxication without Perceptual Disturbances with Use Disorder, MODERATE or SEVERE	F12.229
	Cannal	bis Intoxication without Perceptual Disturbances without Use Disorder	F12.929
	Sedati	ive. Hvonotic, or Anviolutic Use Disorder, MILD	F13.10
		ive. Hypnotic, or Anxiolytic Use Disorder, MODERATE or SEVERE	F13.20
		ive. Hypnotic. or Anxiolytic Use Disorder, Mild in early or sustained REMISSION	F13.11
	-	ive, Hypnotic, or Anxiolytic Use Disorder, Moderate or Severe in early or sustained REMISSION	F13.21
		ve, Hypnotic, or Anxiolytic Intoxication with Use Disorder, MILD	F13.129
┶╌┵╼┨┠╌┸╴┸╶┸╴┸╴┸╴┸	J	ve, Hypnotic, or Anxiolytic Intoxication with Use Disorder, MODERATE or SEVERE	F13.229
		ive, Hypnotic, or Anxiolytic Intoxication without Use Disorder	F13.929
		ive, Hypnotic, or Anxiolytic Withdrawal without Perceptual Disturbances with Use Disorder, MODERATE or SEVERE	F13.239
	Cocain	ne Use Disorder, MILD	F14.10
	Cocain	ne Use Disorder, MODERATE or SEVERE	F14.20
	Cocain	ne Use Disorder, Mild in early or sustained REMISSION	F14.11
		ne Use Disorder, Moderate or Severe in early or sustained REMISSION	F14.21
	1	ne Intoxication. without Perceptual Disturbances with Use Disorder. MILD	F14.129
Cocaine Introxication without Perceptual Disturbances without Use Disorder		le Intoxication without Perceptual Disturbances with Use Disorder, MODERATE or SEVERE	F14.229
Possing Mikhdemusi	Cocain	e Intoxication without Perceptual Disturbances without Use Disorder	F14.929
	Cocain	Cocaine Withdrawal	F14.23

Amphetamine-Type Substance Example: Methamphetamine (crystal meth.crank.		E1E 20
Amphetamine-Type Substance Example: Methamphetamine (crystal meth. crank.	Amphetamine-Type Substance Use Disorder, MODERATE or SEVERE	07.017
Example: Methamphetamine (crystal meth.crank.	Am phetamine-Type Substance Use Disorder, Mild in early or sustained REMISSION	F15.11
	Am phetamine-Type Substance Use Disorder, Moderate or Severe in early or sustained REMISSION	F15.21
speed, tweek, glass, etc.)	Amphetamine-Type Substance Intoxication without Perceptual Disturbances with Use Disorder, MILD	F15.129
	Amphetamine-Type Substance Intoxication without Perceptual Disturbances with Use Disorder. MODERATE or SEVERE	F15.229
	Amphetamine-Type Substance Intoxication without Perceptual Disturbances without Use Disorder	15.929
	Amphetamine-Type Substance Withdrawal	F15.23
	Other or Unspecified Stimulant Use Disorder, MILD	F15.10
	Other or Unspecified Stimulant Use Disorder, MODERATE or SEVERE	F15.20
Other or Unspecified Stimulant	Other or Unspecified Stimulant Use Disorder, Mild in early or sustained REMISSION	F15.11
Example: Ritalin (methylphenidate), Adderall	Other or Unspecified Stimulant Use Disorder, Moderate or Severe in early or sustained REMISSION	F15.21
(dextroamphetamine/ amphetamine), Vyvanse,	Other Stimulant Intoxication without Perceptual Disturbances with Use Disorder, MILD	F15.129
(lisdexamfetamine), etc.	Other Stimulant Intoxication without Perceptual Disturbances with Use Disorder, MODERATE or SEVERE	F15.229
	Other Stimulant Intoxication without Perceptual Disturbances without Use Disorder	F15.929
	Other Stimulant Withdrawal	F15.23
	Bhanaculidina (DCD11ta Diracular MILD	E16.10
	ritensystatic (rcr) / 055 disordaet) mice Dhanacaididin (rcr) (1160 disordaet) mice	E16.20
		L 10.2.0
Phencyclidine	Phencyclidine (PCP) Use Disorder, Mild in early or sustained REMISSION	F16.11
Example: PCP (phencyclidine)	Phencyclidine (PCP) Use Disorder, Moderate or Severe in early or sustained REMISSION	F16.21
	Phencyclidine (PCP) Intoxication with Use Disorder, MILD	F16.129
	Phencyclidine (PCP) Intoxication with Use Disorder, MODERATE or SEVERE	F16.229
	Phencyclidine (PCP) Intoxication without Use Disorder	F16.929
	Other Hallucinosen Use Disorder. MILD	F16.10
	Other Hallucinosen Use Disorder MODEBATE or SEVERE	F16.20
Other Hallucinogen	Other Hallucinesen Use Disorder Mild in early or sustained REMISSION	F16.11
Example: LSD (acid), Ecstasy (MDMA), Ketamine,	other Hallucinogen ees energien in manual and an energien and an energien and an Anderse and an energiente and an Anderse and an energiente and an Anderse and an and an and an and an and and and	E16.31
magic mushrooms (Psilocybin), Peyote (Mescaline),		L10.21
etc.	Other Hallucinogen Intoxication with Use Disorder, MLD	F16.129
	Other Hallucinogen Intoxication with Use Disorder, MODERATE or SEVERE	F16.229
	Other Hallucinogen Intoxication without Use Disorder	F16.929
	Inhalant Use Disorder, MILD	F18.10
	Inhalant Ilee Disorder MODERATE or SEVERE	F18.20
	Internet teo Discreter Mild in activer cursting REMISSION	E18.11
Inhalant	la bela de la constante de Mardarata a restante a transforma de EMIRCION.	E10.31
Example: Glues, spray cans, etc.		L10.21
	Inhalant Intoxication with Use Disorder, MILD	F18.129
	Inhalant Intoxication with Use Disorder, MODERATE or SEVERE	F18.229
	Inhalant Intoxication without Use Disorder	F18.929
	Other (or Unknown) Substance Use Disorder. MILD	F19.10
	Other (or Unknown) Substance Use Disorder. MODERATE or SEVERE	F19.20
	Other for Unknown) Substance Use Disorder. Mild in early or sustained REMISSION	F19.11
	other for laminum (substantion of protocol) of Madata Andreas of Substantion (substantion) of Madata (substantion) of the Substantian (substantion) of the Substantian (substantian) of t	10.11
Other (or Unknown) Substance	Utilet (u) Utilitiumi jaudskatike Ose disutuet, imudetake u) severe tit early ui suskatileu kelmissi ON	17.61
	Other (or Unknown) Substance Intoxication with Use Disorder, MILD	F19.129
	Other (or Unknown) Substance Intoxication with Use Disorder, MODERATE or SEVERE	F19.229
	Other (or Unknown) Substance Intoxication without Use Disorder	F19.929
	Other (or Unknown) Substance Withdrawal	F19.239

BHS/SUD

	AT	BEHAVIORAL HEALTH Abuseo of come constability former COHOL & OTHER DRUG SERVICES						
	DI	AGNOSIS REFERENCE GUIDE						
-		stance Use Disorder						
See DSM-5 for o	criteria specific to the dru	igs identified as primary, secondary or tertiary.						
	rimary, S=Secondary, T=							
	 Substance is often taken in larger amounts and/or over a longer period than the patient intended. 							
	2. Persistent attempts or one or more unsuccessful efforts made to cut down or control substance							
	use. 3. A great deal of time	e is spent in activities necessary to obtain the substance, use the substance						
	 A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from effects. 							
	4. Craving or strong desire or urge to use the substance							
	Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or homo							
	 home. 6. Continued substance use despite having persistent or recurrent social or interpersonal problem caused or exacerbated by the effects of the substance. 							
		ccupational or recreational activities given up or reduced because of						
	substance use.							
	8. Recurrent substance use in situations in which it is physically hazardous.							
	Substance use is contract.	ontinued despite knowledge of having a persistent or recurrent physical or						
	psychological problem	that is likely to have been caused or exacerbated by the substance.						
	psychological problem 10. Tolerance, as defir	that is likely to have been caused or exacerbated by the substance. ned by either of the following:						
	psychological problem 10. Tolerance, as defir a. Markedly increased	that is likely to have been caused or exacerbated by the substance.						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which:	that is likely to have been caused or exacerbated by the substance. ned by either of the following: a amounts of the substance in order to achieve intoxication or desired effect;						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe	that is likely to have been caused or exacerbated by the substance. ned by either of the following:						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which:	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; d effect with continued use of the same amount;						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; d effect with continued use of the same amount; nifested by either of the following:						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; d effect with continued use of the same amount;						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which:	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; d effect with continued use of the same amount; nifested by either of the following:						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which:	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; d effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance;						
	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which:	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; d effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance;						
Diagnostic and	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which:	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms;						
Diagnostic and	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: Statistical Manual of M sorder (ICD 10)	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms;						
Diagnostic and 305.00 (F10)	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminisher Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: Statistical Manual of M sorder (ICD 10) .10) Mild	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; inifested by either of the following: withdrawal syndrome for the substance; issely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes						
Diagnostic and Alcohol Use Di 305.00 (F10 303.90(F10.	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminisher Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: Statistical Manual of M sorder (ICD 10) .10) Mild 20) Moderate	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; inifested by either of the following: withdrawal syndrome for the substance; issely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present						
Diagnostic and Alcohol Use Dia 305.00 (F10 303.90(F10.	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminisher Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: 15tatistical Manual of M sorder (ICD 10) .10) Mild 20) Moderate 20) Severe	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; resely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present						
Diagnostic and Alcohol Use Di 305.00 (F10 303.90(F10. 303.90(F10.	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: d. The same (or a clo Which: 1 Statistical Manual of M sorder (ICD 10) .10) Mild 20) Moderate 20) Severe Use Disorder	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; resely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present						
Diagnostic and Alcohol Use Dia 305.00 (F10) 303.90(F10. 303.90(F10. 303.90(F10. 303.90(F10. 0. 305.90 (F16)	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: b. The same (or a clo Which: 1 Statistical Manual of M sorder (ICD 10) .10) Mild 20) Moderate 20) Severe Use Disorder .10) Mild	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present 6+ symptoms present						
Diagnostic and Alcohol Use Di 305.00 (F10 303.90(F10. 303.90(F10. 0 303.90(F16) 305.90 (F16 305.90 (F16) 305.90 (F16) 3	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: b. The same (or a clo Which: 1 Statistical Manual of M sorder (ICD 10) .10) Mild 20) Moderate 20) Severe Use Disorder .10) Mild .20) Moderate	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present 6+ symptoms present 2-3 symptoms present						
Alcohol Use Di 305.00 (F10 303.90(F10. 303.90(F10. Phencyclidine 305.90 (F16 304.60 (F16	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: b. The same (or a clo Which: clo Moderate clo b. Moderate clo b. Severe clo b. Severe clo clo b. Severe clo clo clo clo clo clo clo clo	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present 4-5 symptoms present 4-5 symptoms present 4-5 symptoms present						
Diagnostic and Alcohol Use Dii 305.00 (F10) 303.90(F10. 900.900 (F10) 303.90(F10. 100.000 (F10) 303.90(F10. 100.000 (F10) 100.000 (F16) 100.000 (F16) <td>psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: b. The same (or a clo Which: c. The same (or</td> <td>that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present 4-5 symptoms present 4-5 symptoms present 4-5 symptoms present</td>	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic Which: b. The same (or a clo Which: b. The same (or a clo Which: c. The same (or	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; nifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present 4-5 symptoms present 4-5 symptoms present 4-5 symptoms present						
Diagnostic and Alcohol Use Dia 305.00 (F10) 303.90(F10. 303.90(F10. 303.90(F10. 303.90(F10. 303.90(F10. 1000000000000000000000000000000000000	psychological problem 10. Tolerance, as defir a. Markedly increased Which: b. Markedly diminishe Which: 11. Withdrawal, as ma a. The characteristic of Which: b. The same (or a clo Which: b. The same (or a clo Which: c. The same (or a clo Which: b. The same (or a clo Which: c. The same (or a clo Whidh 20) Moderate 20) Severe isorder: .10) Mild	that is likely to have been caused or exacerbated by the substance. hed by either of the following: a amounts of the substance in order to achieve intoxication or desired effect; ded effect with continued use of the same amount; mifested by either of the following: withdrawal syndrome for the substance; usely related) substance is taken to relieve or avoid withdrawal symptoms; Mental Disorders, Fifth Edition – Diagnostic Codes 2-3 symptoms present 4-5 symptoms present 6+ sym						

	- Ma											
	CONTRA COSTA											
	BEHAVIORAL HEALTH A Demon of Contra Cata Health Series ALCOHOL & OTHER DRUG SERVICES											
ALCOHOL & OTHER DRUG SERVICES												
	Stimulant Use Disorder											
	Mild: Presence of 2-3 symptoms											
30	· ·		Amphetamine-type substance									
30			Cocaine									
	305.70 (F15.10) Other or unspecified stimulant											
	Moderate: Presence of 4-5 sym			-								
	□ 304.40 (F15.20)		Amphetamine-type substance Cocaine									
	□ 304.20 (F14.20)											
	304.40 (F15.10) Other or unspecified stimulant Severe: Presence of 6 or more symptoms											
□ 304					substance							
	□ 304.20 (F15.20)		Amphetamine-type substance Cocaine									
□ 304				unspecified	l stimulant							
	304.40(F15.10)Other or unspecified stimulant											
Canna	ibis Use Disorder											
30	5.20 (F12.10)	Mild	2-3	3 sympton	ns present							
□ 304	4.30 (F12.20)	Moderate	4-5	5 symptom	ns present							
☐ 30-	4.30 (F12.20)	Severe	6+	symptom	ns present							
Other		Discusion										
	Hallucinogen Use	Mild	Dre	acres of f	2 aumatama							
□ 304 □ 304		Moderate			2-3 symptoms -5 symptoms							
☐ 304 ☐ 304		Severe		sence of 6								
	1.00	OCVCIC	110									
Opioid	d Use Disorder											
305	5.50 (F11.10)	Mild	2-3	symptom	s present							
304	1.00 (F11.20)	Moderate	4-5	symptom	s present							
304	304.00 (F11.20) Seve		6+	symptom	s present							
Sadati	ivo Uvonatia ar A	nviolutio II		rdor								
	ive, Hypnotic, or A 5.40 (F13.10)	Mild		symptom	e procont							
	1.10 (F13.20)	Moderate		symptom	-							
	10 (F13.20)	Severe		symptom								
		501010	01	53mptom								
Tobac	co Use Disorder											
305	5.10 (Z72.0)	Mild	2-3	symptom	s present							
304	1.10 (F17.20)	Moderate	4-5	symptom	s present							
304	1.10 (F17.20)	Severe	6+	symptom	s present							
🗌 Ado	ditional Specifiers			• • • • • • • • • • • • • • • • • • •								
	eening of substance		led incut	ficient ever	intoms to indico	te abuse or addic	tion					
	cerning of subsidifice	ase reveal	115UI	noient Syll	iptome to muica		uun.					
Name						Date		·····				
Dia						Orectential						
Diagn	osis by					Credential						
DSM-5	DSM-5 SUD Diagnosis Reference Guide CCCAODS pg. 2											

REFERENCES

- Adenauer, H., Catani, C., Gola, H., Keil, J., Ruf, M., Schauer, M., & Neuner, F. (2011). Narrative exposure therapy for PTSD increases top-down processing of aversive stimulievidence from a randomized controlled treatment trial. *BMC Neuroscience*, 12(1), 127.
- Alvarez, J., McLean, C., Harris, A. H., Rosen, C. S., Ruzek, J. I., & Kimerling, R. (2011). The comparative effectiveness of cognitive processing therapy for male veterans treated in a VHA posttraumatic stress disorder residential rehabilitation program. *Journal of Consulting and Clinical Psychology*, 79(5), 590.
- American Psychiatric Association, & American Psychiatric Association. *Diagnostic and statistical manual of mental disorders* (1980) Washington. DC: Author.
- American Psychiatric Association. (2004). *Practice guidelines for the treatment of patients with acute stress disorder and posttraumatic stress disorder*. Arlington, VA:.
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders (DSM- 5)* (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Anker, M., Duncan, B., & Sparks, J. (2009). Using client feedback to improve couple therapy outcomes: A randomized clinical trial in a naturalistic setting. *Journal of Consulting and Clinical Psychology*, 77(4), 693.
- Anthenelli, R. M. (2010). Focus on: Comorbid mental health disorders. *Alcohol Research & Health*, *33*(1-2), 109-117.
- Arnow, B., Steidtmann, D., Blasey, C., Manber, R., Constantino, J., Klein, N., & Kocsis, J. H. (2013). The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. *Journal of Consulting and Clinical Psychology*, 81(4), 627.
- Australian Centre for Posttraumatic Mental Health. (2007). *Australian guidelines for the treatment of adults with acute stress disorder and posttraumatic stress disorder.* National Health and Medical Research Council.
- Back SE, Dansky BS, Coffey SF, Saladin ME, Sonne S, Brady KT. Cocaine dependence with and without post-traumatic stress disorder: A comparison of substance use, trauma history and psychiatric comorbidity. The American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2000;9(1):51–62. [PubMed: 10914293]
- Ball, G., Stokes, P. R., Rhodes, R. A., Bose, S. K., Rezek, I., Wink, A.-M., . . . Turkheimer, F. E. (2011). Executive functions and prefrontal cortex: A matter of persistence? *Frontiers in Systems Neuroscience*, *5*(3), 1-13.
- Baranowsky, A. B., & Gentry, J. E. (2014). *Trauma practice: Tools for stabilization and recovery* (3rd ed.). New York, NY: Hogrefe & Huber. doi:10.1027/00471-000
- Barkham, M., Hardy, G. E., & Mellor-Clark, J. (2010). Developing and delivering practicebased evidence. *A guide for the psychological therapies*. John Wiley & Sons, Ltd
- Becker, J. B., & Koob, G. F. (2016). Sex differences in animal models: Focus on addiction. *Pharmacological Reviews, 68*(2), 242-263.

- Belin, D., Jonkman, S., Dickinson, A., Robbins, T. W., & Everitt, B. J. (2009). Parallel and interactive learning processes within the basal ganglia: Relevance for the understanding of addiction. *Behavioural Brain Research*, 199(1), 89-102.
- Benedek, D. M., & Wynn, G. H. (Eds.). (2016). *Complementary and Alternative Medicine for PTSD*. Oxford University Press.
- Benish, S. G., Imel, Z. E., & Wampold, B. E. (2008). The relative efficacy of bona fide psychotherapies for treating post-traumatic stress disorder: A meta-analysis of direct comparisons. *Clinical Psychology Review*, 28, 746–758. doi:10.1016/j.cpr.2007.10.005
- Benson, H. (1997). The relaxation response: therapeutic effect. *Science*, 278(5344), 1694.
- Berceli, D. (2005). *Trauma releasing exercises (TRE): A revolutionary new method for stress/trauma recovery*. BookSurge.
- Berceli, D. (2007). *Evaluating the effects of stress reduction* exercises (Doctoral dissertation, Arizona State University).
- Bercelli, D. (2009). *The revolutionary trauma release process: Transcend your toughest times*. Namaste: Vancouver, BC
- Bergmann, U. (2012). *Neurobiological foundations for EMDR practice*. New York: Springer.
- Berlin, G. S., & Hollander, E. (2014). Compulsivity, impulsivity, and the DSM-5 process. *CNS Spectrums, 19*(1), 62-68.
- Bernstein EM, Putnam FW (1986). Development, reliability, and validity of a dissociation scale. *Journal of Nervous and Mental Disease*, 174 (12): 727–35.
- Bernstein, E., Putnam, F. W., Ross, C. A., Torem, M., Coons, P., Dill, D., ... & Braun, B. G. (1993). Validity of the Dissociative Experiences Scale in screening for multiple personality disorder: A multicenter study. *Am J Psychiatry*, *150*, 1030-1036.
- Bisson, J. I., Ehlers, A., Matthews, R., Pilling, S., Richards, D., & Turner, S. (2007). Psychological treatments for chronic post-traumatic stress disorder: Systematic review and meta-analysis. *The British Journal of Psychiatry*, 190(2), 97–104.
- Bisson, J., & Andrew, M. (2009). Psychological treatment of post-traumatic stress disorder. *The Cochrane Library*, 3, 1–118.
- Bloom, S. L. (1997). *Creating sanctuary: Toward the evolution of sane societies*. New York, NY: Routledge.
- Bonner, R. L., & Rich, A. (1988). Negative life stress, social problem-solving selfappraisal, and hopelessness: Implications for suicide research. *Cognitive Therapy and Research*, 12(6), 549- 556.
- Boudewyns, P. A., & Hyer, L. (1990). Physiological response to combat memories and preliminary treatment outcome in Vietnam veteran PTSD patients treated with direct therapeutic exposure. *Behavior Therapy*, 21(1), 63–87.
- Bovin, M. J., & Weathers, F. W. (2012). Assessing PTSD symptoms. Oxford Library of Psychology. *The Oxford handbook of traumatic stress disorders*, 235-249.
- Bovin, M. J., Marx, B. P., Weathers, F. W., Gallagher, M. W., Rodriguez, P., Schnurr, P. P., & Keane, T. M. (2016). Psychometric properties of the PTSD Checklist for Diagnostic and

Statistical Manual of Mental Disorders–Fifth Edition (PCL-5) in veterans. *Psychological Assessment*, 28(11), 1379.

- Brady, K. T., & Randall, C. L. (1999). Gender differences in substance use disorders. *Psychiatric Clinics of North America*, 22(2), 241-252.
- Breslau, N., & Kessler, R. C. (2001). The stressor criterion in DSM-IV posttraumatic stress disorder: an empirical investigation. *Biological Psychiatry*, 50(9), 699-704.
- Breslau, N., Kessler, R., & Peterson, E. L. (1998). Post-traumatic stress disorder assessment with a structured interview: reliability and concordance with a standardized clinical interview. *International Journal of Methods in Psychiatric Research*, 7(3), 121-127.
- Briere, J., & Scott, C. (2014). *Principles of trauma therapy: A guide to symptoms, evaluation, and treatment* (2nd ed.). Thousand Oaks, CA: Sage.
- Brooks, P. J., Enoch, M.-A., Goldman, D., Li, T.-K., & Yokoyama, A. (2009). The alcohol flushing response: An unrecognized risk factor for esophageal cancer from alcohol consumption. *PLOS Medicine*, *6*(3).
- Brown PJ, Recupero PR, Stout R. PTSD substance abuse comorbidity and treatment utilization. Addictive Behaviors 1995;20(2):251–254. [PubMed: 7484319]
- Brown PJ, Stout RL, Mueller T. Substance use disorder and posttraumatic stress disorder comorbidity: Addiction and psychiatric treatment rates. Psychology of Addictive Behaviors 1999;13(2):115–122.
- Brown, W. J., Dewey, D., Bunnell, B. E., Boyd, S. J., Wilkerson, A. K., Mitchell, M. A., & Bruce, S. E. (2016). A Critical Review of Negative Affect and the Application of CBT for PTSD. *Trauma, Violence, & Abuse*, 1524838016650188.
- Buckner, J. D., Zvolensky, M. J., Ecker, A. H., & Jeffries, E. R. (2016). Cannabis craving in response to laboratory-induced social stress among racially diverse cannabis users: The impact of social anxiety disorder. *Journal of Psychopharmacology 30*(4), 363-369.
- Cacciola JS, Alterman AI, McKay JR, Rutherford MJ. Psychiatric comorbidity in patients with substance use disorders: Do not forget axis II disorders. Psychiatric Annals 2001;31:321–331.
- Cacciola JS, Koppenhaver J, Alterman AI, McKay JR. Posttraumatic stress disorder and other psychopathology in substance abusing patients. Drug and Alcohol Dependence 2009;101(12):27–33. [PubMed: 19062202]
- Cahill, S. P., Rothbaum, B. O., Resick, P. A., & Follette, V. M. (2009). Cognitive-behavioral therapy for adults. In E. B. Foa, T. M. Keane, M. J. Friedman, & J. A. Cohen (Eds.), *Effective treatments for PTSD: Practice guides from the International Society for Traumatic Stress Disorders* (2nd ed., pp. 617–639). New York, NY: Guilford Press.
- Calhoun, L. G., & Tedeschi, R. G. (2001). Posttraumatic growth. *Corsini Encyclopedia of Psychology*.
- Calhoun, L. G., & Tedeschi, R. G. (2014). *Handbook of posttraumatic growth: Research and practice*. Routledge.
- Carbonell, J. L., & Figley, C. (1999). Running head: Promising PTSD Treatment Approaches A Systematic Clinical Demonstration of Promising PTSD Treatment Approaches. *Traumatology*, 5(1), 32-48.

- Carbonell, J., & Figley, C. (1996). A systematic clinical demonstration methodology: A collaboration between practitioners and clinical researchers. *Traumatology*, 2(1), 1–6.
- Center for Behavioral Health Statistics and Quality. (2016). *Results from the 2015 National Survey on Drug Use and Health: Detailed tables*. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- Chanraud, S., Pitel, A.-L., Müller-Oehring, E. M., Pfefferbaum, A., & Sullivan, E. V. (2013). Remapping the brain to compensate for impairment in recovering alcoholics. *Cerebral Cortex*, 23(1), 97-104.
- Chemtob, C. M., Nakashima, J., & Carlson, J. G. (2002). Brief treatment for elementary school children with disaster-related posttraumatic stress disorder: a field study. *Journal of Clinical* Psychology, 58(1), 99+
- Chilcoat, H. D., & Menard, C. (2003). Epidemiological investigations: Comorbidity of posttraumatic stress disorder and substance use disorder. In P. Ouimette & P. J. Brown (Eds.), *Trauma and substance abuse: Causes, consequences, and treatment of comorbid disorders.* (pp. 9-28). Washington, DC: American Psychological Association.
- Chow, D. L., Miller, S. D., Seidel, J. A., Kane, R. T., Thornton, J. A., & Andrews, W. P. (2015). The role of deliberate practice in the development of highly effective psychotherapists. *Psychotherapy*, 52(3), 337.
- Clapp, P., Bhave, S. V., & Hoffman, P. L. (2008). How adaptation of the brain to alcohol leads to dependence: A pharmacological perspective. *Alcohol Research & Health, 31*(4), 310-339.
- Cloitre, M., Courtois, C. A., Charuvastra, A., Carapezza, R., Stolbach, B. C., & Green, B. L. (2011). Treatment of complex PTSD: Results of the ISTSS expert clinician survey on best practices. *Journal of Traumatic Stress*, 24, 615–627. doi:10.1002/jts.20697
- Cloitre, M., Courtois, C. A., Ford, J. D., Green, B. L., Alexander, P., Briere, J., & Van der Hart, O. (2012). *The ISTSS expert consensus treatment guidelines for complex PTSD in adults.* Retrieved from https://www.istss.org/ISTSS_Main/media/Documents/ISTSS-Expert-Concesnsus-Guidelines-for-Complex-PTSD. Updated-060315.pdf
- Cloitre, M.; Garvert, D. W.; Brewin, C. R.; Bryant, R. A.; & Maercker, A. (2013) Evidence forproposed ICD-11 PTSD and complex PTSD: a latent profile analysis. *European Journal of Psychotraumatology*, 4(1), retrieved from https://doi.org/10.3402/ejpt.v4i0.20706
- Cloitre, M.; Garvert, D. W.; Weiss, B.; Carlson, E. B.; & Bryant, R. A. (2014) Distinguishing PTSD,Complex PTSD, and Borderline Personality Disorder: A latent class analysis. *European Journal of Psychotraumatology* 5(1)
- Cohen LR, Hien DA. Treatment outcomes for women with substance abuse and PTSD who have experienced complex trauma. Psychiatric Services (Washington, D.C.) 2006;57(1):100–106.
- Cohen, J. A., Mannarino, A. P., & Deblinger, E. (2016). *Treating trauma and traumatic grief in children and adolescents*. Guilford Publications.
- Connor, J. P., Gullo, M. J., White, A., & Kelly, A. B. (2014). Polysubstance use: Diagnostic challenges, patterns of use and health. *Current Opinion in Psychiatry*, *27*(4), 269-275.

- Connors, G. J., DiClemente, C. C., Dermen, K. H., Kadden, R., Carrol, K. M., & Fronne, M. R. (2000). Predicting the therapeutic alliance in alcoholism treatment. *Journal of Studies on Alcohol*, 61(1), 139
- Corrigan, F. M. (2002). Mindfulness, dissociation, EMDR and the anterior cingulate cortex: A hypothesis. *Contemporary Hypnosis*, 19, 8–17.
- Corrigan, F. M., & Hull, A. M. (2015). Neglect of the complex: why psychotherapy for posttraumatic, clinical presentations is often ineffective. *B J Psych Bulletin*, 39(2), 86–89.
- Courtois C. & Pearlman, L. (2005) Clinical applications of the attachment framework: relational treatment of complex trauma. *Journal of Trauma Stress*. 18(5):449-459.
- Courtois, C. A., & Ford, J. D. (Eds.). (2009). *Treating complex traumatic stress disorders: An evidence-based guide*. Guilford Press.
- Cox, C.L. (1992). Perceived threat as a cognitive component of state anxiety and confidence. *Perception and Motor Skills*, 75(3:2), 1092-1094.
- Cozolino, L. (2014). *The neuroscience of human relationships: Attachment and the developing social brain.* New York: Norton.
- Cozolino, L. O. U. I. S. (2006). The social brain. *Psychotherapy in Australia*, 12(2), 12.
- Critchley, H. D., Melmed, R. N., Featherstone, E., Mathias, C. J., & Dolan, R. J. (2001). Brain activity during biofeedback relaxation A functional neuroimaging investigation. *Brain*, 124(5), 1003-1012.
- Crowder, J. A., Taylor, J.M., & Raskin, V. (2012, July). *Autonomous creation and detection of procedural memory scripts*. In Proceedings of the 13th annual international conference on artificial intelligence, Las Vegas.
- Crunelle, C. L., Kaag, A. M., van den Munkhof, H. E., Reneman, L., Homberg, J. R., Sabbe, B., . . . van Wingen, G. (2015). Dysfunctional amygdala activation and connectivity with the prefrontal cortex in current cocaine users. *Human Brain Mapping*, *36*(10), 4222-4230.
- Csikszentmihalyi, M. (1997). *Finding flow: The psychology of engagement with everyday life*. Basic Books.
- Curran, L. A. (2009). *Trauma competency: A clinician's guide*. PESI Publishing & Media.
- Dansky BS, Brady KT, Saladin ME, Killeen T, Becker S, Roitzsch JC. Victimization and PTSD in individuals with substance use disorders: Gender and racial differences. The American Journal of Drug and Alcohol Abuse 1996;22(1):75–93. [PubMed: 8651146]
- Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010). Phasic vs sustained fear in rats and humans: Role of the extended amygdala in fear vs anxiety. *Neuropsychopharmacology*, 35(1), 105-135.
- Dick, D. M., & Agrawal, A. (2008). The genetics of alcohol and other drug dependence. *Alcohol Research & Health, 31*(2), 111-119.
- Drgonova, J., Walther, D., Singhal, S., Johnson, K., Kessler, B., Troncoso, J., & Uhl, G. R. (2015). Altered CSMD1 expression alters cocaine-conditioned place preference: Mutual support for a complex locus from human and mouse models. *PLOS ONE*, *10*(7).
- Dube, S. R., Felitti, V. J., Dong, M., Chapman, D. P., Giles, W. H., & Anda, R. F. (2003). Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: The adverse childhood experiences study. *Pediatrics*, *111*(3), 564-572.

- Ewing, John A. (1984) "Detecting Alcoholism: The CAGE Questionnaire" JAMA 252: 1905-1907.
- •
- Fukuda, K., Yuzuriha, T., Kinukawa, N., Murakawa, R., Takashima, Y., Uchino, A., . . . Hirano, M. (2009). Alcohol intake and quantitative MRI findings among community dwelling Japanese subjects. *Journal of the Neurological Sciences, 278*(1), 30-34.
- Giedd, J. N., Blumenthal, J., Jeffries, N. O., Castellanos, F. X., Liu, H., Zijdenbos, A., . . . Rapoport, J. L. (1999). Brain development during childhood and adolescence: A longitudinal MRI study. *Nature Neuroscience*, *2*(10), 861-863.
- Goldstein, R. Z., & Volkow, N. D. (2002). Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. *American Journal of Psychiatry*, *159*(10), 1642-1652.
- Goldstein, R. Z., & Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications. *Nature Reviews Neuroscience*, *12*(11), 652-669.
- Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., . . . Kaplan, K. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry*, *61*(8), 807-816.
- Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Ruan, W. J., & Pickering, R. P. (2004). Co- occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry*, *61*(4), 361-368.
- Greenfield, S. F., Back, S. E., Lawson, K., & Brady, K. T. (2010). Substance abuse in women. *Psychiatric Clinics of North America*, *33*(2), 339-355.
- Hammond, CJ & Sharma, P. (2017). Treatment strategies for substance use disorders in adolescents: A clinical review. Psychiatric Times, 30(6).
- Hanson, K. L., Medina, K. L., Padula, C. B., Tapert, S. F., & Brown, S. A. (2011). Impact of adolescent alcohol and drug use on neuropsychological functioning in young adulthood: 10- year outcomes. *Journal of Child and Adolescent Substance Abuse, 20*(2), 135-154.
- Hasin, D. S., & Grant, B. F. (2015). The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: Review and summary of findings. *Social Psychiatry and Psychiatric Epidemiology*, *50*(11), 1609-1640.
- Heishman, S. J., Singleton, E. G., & Liguori, A. (2001). Marijuana craving questionnaire: Development and initial validation of a self-report instrument. *Addiction*, *96*(7), 1023-1034.
- Holmes, A., Fitzgerald, P. J., MacPherson, K. P., DeBrouse, L., Colacicco, G., Flynn, S. M., Marcinkiewcz, C. A. (2012). Chronic alcohol remodels prefrontal neurons and disrupts NMDAR- mediated fear extinction encoding. *Nature Neuroscience*, *15*(10), 1359-1361.
- Hser, Y.-I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of narcotics addicts. *Archives of General Psychiatry*, *58*(5), 503-508.

- Hubbard, R. L., Craddock, S. G., & Anderson, J. (2003). Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). *Journal of Substance Abuse Treatment, 25*(3), 125-134.
- Hunsley, J, Mash, E. (2008). A Guide to Assessments that Work. New York, NY: Oxford Press.
- •
- Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: A review of the literature. American Journal of Psychiatry 2001;158(8):1184–1190. [PubMed: 11481147]
- Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001). Substance use disorders in patients with posttraumatic stress disorder: A review of the literature. *American Journal of Psychiatry*, *158*(8), 1184-1190.
- Kalivas, P. W. (2009). The glutamate homeostasis hypothesis of addiction. *Nature Reviews Neuroscience*, *10*(8), 561-572.
- Kalivas, P. W., & Volkow, N. D. (2005). The neural basis of addiction: A pathology of motivation and choice. *The American Journal of Psychiatry*, *162*(8), 1403-1413.
- Kann, L., Kinchen, S., Shanklin, S. L., Flint, K. H., Hawkins, J., Harris, W. A., ... & Whittle, L. (2014). Youth risk behavior surveillance—United States, 2013. *Morbidity and Mortality Weekly Report: Surveillance Summaries*, *63*(4), 1-168.
- Kaskutas, L.A. (2009). Alcoholics Anonymous Effectiveness: Faith Meets Science. *Journal* of Addictive Diseases, 28(2), 145–157.
- Kelley, M. E., Wan, C. R., Broussard, B., Crisafio, A., Cristofaro, S., Johnson, S., . . . Walker, E. F. (2016). Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. *Schizophrenia Research*, 171(1-3), 62-67.
- Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry, 62*(6), 593-602.
- Keyes, K. M., Grant, B. F., & Hasin, D. S. (2008). Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. *Drug and Alcohol Dependence*, *93*(1), 21-29.
- Killeen T, Hien D, Campbell A, Brown C, Hansen C, Jiang H, et al. Adverse events in an integrated trauma-focused intervention for women in community substance abuse treatment. Journal of Substance Abuse Treatment 2008;35:304–311. [PubMed: 18294804]
- Koob, G. F. (2011). Neurobiology of addiction. *Focus*, *9*(1), 55-65.
- Koob, G. F., & Le Moal, M. (1997). Drug abuse: Hedonic homeostatic dysregulation. *Science*, *278*(5335), 52-58.
- Koob, G. F., & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology*, 24(2), 97-129.
- Koob, G. F., & Le Moal, M. (2005). Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. *Nature Neuroscience*, 8(11), 1442-1444.

- Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. *Neuropsychopharmacology*, *35*(1), 217–238.
- Koob, G. F., Arends, M. A., & Le Moal, M. (2014). *Drugs, addiction, and the brain*. Waltham, MA: Academic Press.
- Koob, G. F., Karde, D. B., Baler, R. D., & Volkow, N. D. (2015). Pathopsychology of addiction. In A. Tasman, J. Kay, J. A. Lieberman, M. B. First, & M. Riba (Eds.), *Psychiatry*. (4th ed., Vol. 1). New York, NY: Wiley-Blackwell.
- Kosten, T. A., Gawin, F. H., Kosten, T. R., & Rounsaville, B. J. (1993). Gender differences in cocaine use and treatment response. *Journal of Substance Abuse Treatment, 10*(1), 63-66.
- Kumari, V., & Postma, P. (2005). Nicotine use in schizophrenia: The self medication hypotheses. *Neuroscience and Biobehavioral Reviews, 29*(6), 1021-1034.
- Leeies, M., Pagura, J., Sareen, J., & Bolton, J. M. (2010). The use of alcohol and drugs to self- medicate symptoms of posttraumatic stress disorder. *Depression and Anxiety*, 27(8), 731-736.
- Lenz, A. S., Henesy, R., & Callender, K. (2016). Effectiveness of Seeking Safety for Co-Occurring Posttraumatic Stress Disorder and Substance Use. *Journal of Counseling & Development*, *94*(1), 51-61.
- Lundahl, L. H., & Johanson, C. E. (2011). Cue-induced craving for marijuana in cannabisdependent adults. *Experimental and Clinical Psychopharmacology*, *19*(3), 224-230.
- Mahan, A. L., & Ressler, K. J. (2012). Fear conditioning, synaptic plasticity and the amygdala: Implications for posttraumatic stress disorder. *Trends in Neurosciences*, *35*(1), 24-35.
- McGovern, M. P., Lambert-Harris, C., Acquilano, S., Xie, H., Alterman, A. I., & Weiss, R. D. (2009). A cognitive behavioral therapy for co-occurring substance use and posttraumatic stress disorders. *Addictive behaviors*, 34(10), 892–897. doi:10.1016/j.addbeh.2009.03.009
- McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. *JAMA*, *284*(13), 1689-1695.
- Miller W. (1983) Motivational interviewing with problem drinkers. Behavioural Psychotherapy. 11:147-172
- Miller W, Rollnick S (2002) Motivational Interviewing. 2nd Edition. Guilford Press New York and London.
- Mills KL, Lynskey M, Teesson M, Ross J, Darke S. Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): Prevalence and correlates. Drug and Alcohol Dependence 2005;77(3):243–249. [PubMed: 15734224]
- Moreira, F. A., & Dalley, J. W. (2015). Dopamine receptor partial agonists and addiction. *European Journal of Pharmacology*, 752, 112-115.
- Najavits, L. M., Hyman, S. M., Ruglass, L. M., Hien, D. A., & Read, J. P. (2017). *Substance use disorder and trauma*. In S. Gold, J. Cook, & C. Dalenberg (Eds.), Handbook of Trauma Psychology (pp. 195-214): American Psychological Association.

- Najavits, L. M., Hyman, S. M., Ruglass, L. M., Hien, D. A., & Read, J. P. (In press). Substance use disorder and trauma. In S. Gold, J. Cook, & C. Dalenberg (Eds.), *Handbook* of trauma psychology. Washington, DC: American Psychological Association.
- Najavits, L.M. (2002) *Seeking Safety. A treatment manual for PTSD and substance abuse.* New York: Guilford Press.
- Najavits, L.M. (2013). *Seeking Safety HIV guide*. Treatment Innovations, Newton Centre, MA.
- Najavits, L.M. & Hien, D.A. (2013). *Helping vulnerable populations: A comprehensive review of the treatment outcome literature on substance use disorder and PTSD*. Journal of Clinical Psychology: In Session, Vol. 69 (5), 433-479.
- Najavits, LM (2009). *Seeking Safety: An implementation guide*. In A. Rubin & DW Springer (Eds). The Clinician's Guide to Evidence-Based Practice. Hoboken, NJ: John Wiley.
- Nestler, E. J. (2005). Is there a common molecular pathway for addiction? *Nature Neuroscience*, *8*(11), 1445-1449.
- Okuyemi, K. S., Powell, J. N., Savage, C. R., Hall, S. B., Nollen, N., Holsen, L. M., . . . Ahluwalia, J. S. (2006). Clinical and imaging study: Enhanced cue-elicited brain activation in African American compared with Caucasian smokers: An fMRI study. *Addiction Biology*, *11*(1), 97-106.
- Ouimette PC, Moos RH, Finney JW. PTSD treatment and 5-year remission among patients with substance abuse and posttraumatic stress disorders. Journal of Consulting and Clinical Psychology 2003;71(2): 410–414. [PubMed: 12699036]
- Parsons, L. H., & Hurd, Y. L. (2015). Endocannabinoid signalling in reward and addiction. *Nature Reviews Neuroscience*, *16*(10), 579-594.
- Phillips, P. E., Stuber, G. D., Heien, M. L., Wightman, R. M., & Carelli, R. M. (2003). Subsecond dopamine release promotes cocaine seeking. *Nature*, *422*(6932), 614-618.
- Porges, S. W., & Carter, C. S. (2017). Polyvagal theory and the social engagement system. *Complementary and Integrative Treatments in Psychiatric Practice. Washington DC, American Psychiatric Association Publishing*, 221-241.
- Prescott, C. A., & Kendler, K. S. (1999). Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. *AmericanJournal of Psychiatry*, *156*, 34-40.
- Prochaska, J.A., DiClemente, C.C. & Norcross, J.C. (1992) In search of how people change. Applications to addictive behaviour. Am. Psych. 47:1102-1114.
- Rando, K., Hong, K.-I., Bhagwagar, Z., Li, C.-S. R., Bergquist, K., Guarnaccia, J., & Sinha, R. (2011). Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: A prospective study. *American Journal of Psychiatry*, *168*(2), 183-192.
- Schuckit, M. A., Edenberg, H. J., Kalmijn, J., Flury, L., Smith, T. L., Reich, T., . . . Foroud, T. (2001). A genome-wide search for genes that relate to a low level of response to alcohol. *Alcoholism: Clinical and Experimental Research*, *25*(3), 323-329.
- Schultz, W., Dayan, P., & Montague, P. R. (1997). A neural substrate of prediction and reward. *Science*, *275*(5306), 1593-1599.

- Squeglia, L. M., Tapert, S. F., Sullivan, E. V., Jacobus, J., Meloy, M. J., Rolfing, T., & Pfefferbaum, A. (2015). Brain development in heavy-drinking adolescents. *AmericanJournal of Psychiatry*, *172*(6), 532-542.
- Stone, A. L., Becker, L. G., Huber, A. M., & Catalano, R. F. (2012). Review of risk and protective factors of substance use and problem use in emerging adulthood. *Addictive Behaviors*, *37*(7), 747-775.
- Substance Abuse and Mental Health Services Administration, & Center for Behavioral Health Statistics and Quality. (2014). *The TEDS Report: Age of substance use initiation among treatment admissions aged 18 to 30*. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- Swift, R. M., & Aston, E. R. (2015). Pharmacotherapy for alcohol use disorder: Current and emerging therapies. *Harvard Review of Psychiatry*, *23*(2), 122-133.
- Teicher, M. H., & Samson, J. A. (2013). Childhood maltreatment and psychopathology: A case for ecophenotypic variants as clinically and neurobiologically distinct subtypes. *American Journal of Psychiatry, 170*(10), 1114-1133.
- Uslaner, J. M., Acerbo, M. J., Jones, S. A., & Robinson, T. E. (2006). The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine. *Behavioural Brain Research*, *169*(2), 320-324.
- Vaillant, G. E. (1995). *The natural history of alcoholism revisited*. Cambridge, MA: Harvard University Press.
- Vederhus, J. K., & Kristensen, Ø. (2006). High effectiveness of self-help programs after drug addiction therapy. *BMC psychiatry*, 6(1), 35.
- Vendruscolo, L. F., Estey, D., Goodell, V., Macshane, L. G., Logrip, M. L., Schlosburg, J. E., . . . Hunt, H. J. (2015). Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol- dependent individuals. *The Journal of Clinical Investigation*, *125*(8), 3193-3197.
- Volkow, N. D., & Morales, M. (2015). The brain on drugs: From reward to addiction. *Cell*, *162*(4), 712-725.
- Volkow, N. D., Fowler, J. S., Wang, G. J., Hitzemann, R., Logan, J., Schlyer, D. J., . . . Wolf, A. P. (1993). Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. *Synapse*, *14*(2), 169-177.
- Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. *New England Journal of Medicine*, *374*(4), 363-371.
- Volkow, N. D., Tomasi, D., Wang, G. J., Logan, J., Alexoff, D. L., Jayne, M., . . . Du, C. (2014). Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. *Molecular Psychiatry*, *19*(9), 1037-1043.
- Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R., . . . Pappas, N. (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. *Nature*, *386*(6627), 830-833.
- Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Childress, A.-R., . . . Wong, C. (2006). Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. *The Journal of Neuroscience*, *26*(24), 6583-6588.

- Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Jayne, M., . . . Wong, C. (2007). Profound decreases in dopamine release in striatum in detoxified alcoholics: Possible orbitofrontal involvement. *The Journal of Neuroscience*, *27*(46), 12700-12706.
- Wong, D. F., Kuwabara, H., Schretlen, D. J., Bonson, K. R., Zhou, Y., Nandi, A., . . . Kumar, A. (2006). Increased occupancy of dopamine receptors in human striatum during cueelicited cocaine craving. *Neuropsychopharmacology*, *31*(12), 2716-2727.
- Yokoyama, A., & Omori, T. (2003). Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. *Japanese Journal of Clinical Oncology*, 33(3), 111-121.
- Zhong, X., Drgonova, J., Li, C. Y., & Uhl, G. R. (2015). Human cell adhesion molecules: Annotated functional subtypes and overrepresentation of addiction-associated genes. *Annals of the New York Academy of Sciences, 1349*(1), 83-95.



COMPASSION UNLIMITED J. Eric Gentry, PhD

PO Box 937 Phoenix, AZ, 85001 (941) 720-0143

www.forward-facing.com

erigent@icloud.com www.compassionunlimited.com www.aztrauma.org www.kleenmusic.com